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1.1 Preface
This thesis deals with the stress response in a mammalian model and a 
teleost fish model. More specifically it concerns interactions between the immune 
system and the hypothalamus-pituitary-adrenal (HPA) axis in the mouse, and the 
hypothalamus-pituitary-interrenal (HPI) axis in tilapia (Oreochromis mossambicus). 
At first glance these two animal models seem to be fairly different. A closer 
comparison suggests that not only at the molecular, but also at the cellular and the 
organismal level mammals and fish show many homologies, which reflect their 
common evolutionary origin. However, comparative functional studies of both 
models, as presented in this thesis, are scarce.
In this thesis the effects of infection, or injection of bacterial endotoxin, on the 
activity of the HPA/HPI axis are studied in mouse and in fish. Two key messenger 
molecules of the immune system and the HPA/HPI axis are central in this thesis: 
interleukin(IL)-6 and corticotropin-releasing hormone (CRH), respectively. In the 
mouse model, the role of IL-6 in the response of the immune system and the 
stimulation of the HPA axis is studied after infection with micro-organisms such as 
yeast and Gram-negative bacteria, and after injection of bacterial endotoxin. IL-6- 
deficient mice, which are unable to elicit a complete immune response upon 
infection, are used for this purpose. In the fish model, the bioactivity of rat and tilapia 
CRH is compared, and the distribution of CRH in tilapia brain is determined after 
injection of bacterial endotoxin.
In the following paragraph (§1.2) a short introduction to the concept of stress 
will be given. The concept of bi-directional communication between the 
neuroendocrine and the immune system during inflammation is introduced in 
paragraph 1.3. Thereafter, information on interleukins, IL-6 in particular, and on CRH 
is given. Next, information on the different infection models used in this thesis is 
presented (§1.4). Paragraph 1.5 gives the outline of this thesis.
1.2 Stress
All living organisms respond to changes in their environment in order to 
maintain physiological homeostasis (or "steady state"). The effort of the body to 
maintain a stable internal environment in response to a large variety of 
environmental challenges was first described by Claude Bernard (9). Cannon (19) 
emphasized the important function of the adrenal medulla and its main hormone, 
adrenalin, in the response of animals to life-threatening stimuli. The adrenal medulla 
is innervated by the brain via sympathetic neural pathways, and this system is called 
the hypothalamus-sympathetic-adrenal medulla axis. Activation of this system leads 
to the release of adrenalin and noradrenalin. The resulting behavioural response to a 
massive and acute release of adrenalin was referred to as the fight or flight response
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(20). A few years later, the concept of stress was developed by Selye (86, 87). 
Stress can be defined as a condition of disturbed homeostasis, as a result of 
adverse influences (stressors) on an animal (86, 87). Selye identified the 
glucocorticoids produced by the adrenal cortex as very important messengers in the 
response to stressors (the stress response). The release of glucocorticoids is 
effectuated by neuroendocrine stimulation via the hypothalamus-pituitary-adrenal 
cortex axis. Later on, Cannon's concept of fight or flight response was included in 
Selye’s stress concept.
At present the stress response is defined as a series of behavioural and 
physiological responses, which enable the animal to overcome the effects of a 
stressor. These responses involve all levels of animal organisation and are 
collectively called the integrated stress response. Initiation of the stress response 
occurs within the Central Nervous System (CNS) in response to distinct blood-borne, 
neurosensory, or limbic signals (106). When stimuli are experienced as stressors, 
activation of the hypothalamus-sympathetic-adrenal medulla axis and of the HPA 
axis follows (22), and this initiates the organism’s adaptive response. Both axes are 
present in all vertebrates from fish to mammals (30, 69). Stimulation of the 
hypothalamus-sympathetic-adrenal medulla system is an early event in the stress 
response leading to activation and alertness, and mobilization of energy stores. 
Activation of the HPA axis follows immediately and leads to replenishment of energy 
stores via increased concentrations of circulating glucocorticoids. These hormones 
also protect the organism against too intense and damaging defense reactions of the 
body, for instance by moderating immune responses (14, 60).
A key factor in the coordination of the stress response in the CNS is CRH 
(Figure 1), which modulates stress-induced autonomic and behavioural responses. 
In case of a stressful event, CRH secretion from hypothalamic cells is increased 
(71), and as a result adrenocorticotropic hormone (ACTH) is secreted by the pituitary 
gland, which in turn stimulates the adrenal gland to produce glucocorticoids. These 
hormones (cortisol in most animals, corticosterone in others) inhibit growth and 
reproductive and thyroid functions, and modulate metabolic responses, gastric stasis 
and immune responses. In a negative-feedback loop, circulating corticosteroids act 
at hypothalamic or supra-hypothalamic levels to reduce CRH mRNA and peptide 
levels, and on the anterior pituitary gland to reduce ACTH production (46).
The stress concept has been extended in the 1990s to include the response 
to a wide array of influences, including parasitic and bacterial infections (22, 70). 
Cytokines such as IL-1, IL-6 and tumour necrosis factor (TNF) are released by cells 
of the immune system after stimulation by e.g. bacterial endotoxins. The HPA axis 
modulates the stress response to inflammation through regulation of cytokine 
production (suppression of IL-1, IL-6 and TNF, and stimulation of IL-4 and IL-10) and 
by up-regulation of cytokine receptors (16). In addition, there is growing evidence for 
the modulating influences of cytokines on the HPA axis during infections. Thus, there
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is a close interaction between the immune system and the neuroendocrine system, 
found both in higher and in lower vertebrates (for Reviews: 7, 8, 15, 107).
Cytokines / Mediators of inflammation 
Psychogenic / Emotional Stimuli 
Traumatic Stimuli 
Diurnal Rhythms
Pressure Sensitive Baroreceptor Signals
Gluco­
corticoids
from
adrenal
glands
Figure 1. Schematic representation of the regulation of the hypothalamus-pituitary 
adrenal cortex (HPA) axis.
The corticotropin-releasing hormone (CRH) is the central biologic effector which facilitates a 
characteristic behavioural and peripheral response to a stressor. The activation of the CRH neurons is 
regulated by central stimulatory and inhibitory inputs and by multiple negative feedback loops. Solid 
lines represent stimulatory effects and broken lines represent inhibitory effects.
1.3 Immune-neuroendocrine interactions in inflammation
During inflammation not only the immune system but also the HPA axis may 
become activated (23, 43, 96). Upon activation of the HPA axis by infectious or non- 
infectious stimuli the adrenal cortex releases glucocorticoid hormones. The steroid
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cortisone (or Kendall’s compound E) was isolated from the adrenal cortex in the 
1930s (56, 74, 108). It was found to suppress rheumatoid arthritis (39), which led to 
the hypothesis that adrenal glucocorticoids play a significant and moderating role in 
the regulation of immunologic processes during inflammation. From research in the 
1970s and 1980s it has become clear that the communication between the immune 
system and the neuroendocrine system is bi-directional. It was shown that serum 
concentrations of corticosterone, the major glucocorticoid in rodents, were increased 
more than 2-fold in rats and mice at the time of the peak of an immune response to a 
foreign antigen, such as sheep or horse red blood cells (11, 12). Moreover, it was 
demonstrated that physiological levels of corticosterone moderate the immunologic 
response in mice (25). It was hypothesized that immune cells limit their own activity 
by secreting molecules that stimulate the HPA axis, resulting in secretion of adrenal 
glucocorticoids that in turn suppress immune activity. These molecules were found to 
be cytokines, and one important trigger for the activation of the HPA axis during 
stimulation of the immune system is IL-1 (13, 28, 78). The concept emerged that 
cytokines and glucocorticoid hormones represent an immune-neuroendocrine 
regulatory feedback loop: during stimulation of the immune system cytokines 
mediate an increase in plasma corticosterone levels. In turn, glucocorticoids 
suppress immune cell functions and production of cytokines, thereby protecting the 
organism against a harmful overshoot of immune reactions (10, 13, 17, 26, 60).
A number of observations support the idea that the cytokines TNF, IL-1 and 
IL-6 are involved in the stimulation of the HPA axis during infections (96). First, 
administration of toxic bacterial products such as lipopolysaccharide (LPS) to 
rodents induces an increase in plasma levels of ACTH and corticosterone, 
characteristic for an activated HPA axis (27, 31, 78, 112). Second, the release of 
pro-inflammatory cytokines such as TNF, IL-1 and IL-6 is induced during the acute 
phase of the inflammatory response (8, 96). Third, peripheral or central 
(intracerebroventricular) administration of TNF, IL-1 and IL-6 increases ACTH and 
corticosterone release in rats and mice (13, 48, 62, 93, 101). It was postulated that 
the stimulation of the HPA axis during bacterial infections is mediated by these pro- 
inflammatory cytokines (reviewed in 95). Interestingly, in Lewis rats, in which CRH 
secretion is defective, a lower response of the pituitary-adrenal axis to IL-1 is found, 
as well as an enhanced and long-lasting inflammatory response to bacterial cell wall 
induced arthritis (91). Despite these studies, however, the specific individual roles of 
these pro-inflammatory cytokines and their interrelationship in the infection induced 
response of the HPA axis are still not clear. In this thesis the role of IL-6 is 
investigated in the immune-neuroendocrine responses during infection in the mouse.
Although research into the communication between the immune and the 
neuroendocrine systems in lower vertebrates has been initiated relatively recently, 
there is also compelling evidence for the existence of a functional relationship 
between the two regulatory systems in these animals. Notably, for fish some studies 
in this field go back 50 years or more (73). Generally speaking, fish not only share
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many of the regulatory mechanisms identified in mammals as key players in the 
interactions between immune and neuroendocrine systems, but also possess some 
intriguing features that may shed light on archetypical regulatory mechanisms, which 
have been developed earlier in evolution than the origin of land vertebrates. 
Importantly, fish were the first vertebrates to possess lymphocytes and the first 
animals to have truly acquired immune functions (7). The same applies to the system 
responsible for the stress associated surge in circulating corticosteroids. The 
hypothalamus-pituitary-interrenal (HPI) axis in fish is the equivalence of the HPA axis 
in mammals. Neurons in the central nervous system of fishes produce neuropeptides 
such as CRH, and pituitary target cells express proopiomelanocortin (POMC), which, 
depending on the cell type, is processed into ACTH or a-MSH (107). As in mammals, 
ACTH is able to rapidly elevate the synthesis of cortisol in fish. In these animals the 
corticosteroid-producing cells are located in the head kidney, which also is one of the 
most important haematopoietic tissues. This tissue is also referred to as the 
interrenal tissue. In this organ no apparent boundaries exist between endocrine and 
immune cells. The functional relevance of this type of organisation, which is unique 
for fish, has been discussed by Balm (7). Evidence for endocrine modulation of 
immune functions in fish has been reviewed recently by Harris and Bird (38).
1.3.1 Cytokines and interleukins
Cytokines are a complex series of protein cell regulators that mediate immune 
functions. They are primarily involved in host responses to disease or infection. Pro- 
inflammatory cytokines promote inflammation, whereas anti-inflammatory cytokines 
suppress the activity of pro-inflammatory cytokines and thereby reduce inflammation 
and promote healing (29). Cytokines are considered pleiotropic proteins, which 
means that they have multiple, overlapping and sometimes antagonistic functions. 
Different cytokines may exert the same biological actions, which is known as 
redundancy (29, 96). Cytokines have further been classified as hematopoietic growth 
factors, interferons, lymphokines, monokines and chemokines (54). Interleukins 
belong to the group of lymphokines or monokines.
The term "interleukin” originally was introduced to describe messenger 
molecules that signal between leukocytes. Interleukins are involved in processes of 
activation, differentiation, and proliferation of immune cells, and in cell-to-cell 
interactions (5, 41). A definition of interleukins on the basis of their functions is 
problematic since these factors possess a wide spectrum of biological activities. The 
secretion of interleukins is usually not constitutive but via regulated pathways. They 
are synthesized and released after cell activation by infectious or non-infectious 
stimuli. However, some interleukins are autoregulatory: they regulate their own 
synthesis or the expression of their own receptors (5, 63, 67).
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Although evidence for the existence of fish cytokines has long been 
circumstantial, recently teleost homologues for mammalian IL-1 p have been cloned 
and sequenced (42 and references therein). Analysis of the sequences has shown 
that there are no aspartic acid residues in the region of the fish precursor where the 
mammalian precursor is cleaved by IL-1 p converting enzyme (ICE). This implies that 
in fish either the molecule remains uncleaved, or that the precursor is cleaved by a 
different protease. Importantly, expression of fish IL-1 has been shown to be induced 
under the influence of the usual stimuli in mammals, such as LPS. Experimental 
results have further indicated the presence of homologues for more cytokine-like 
factors in fish (44).
1.3.2 Interleukin-6
Interleukin-6 was discovered by molecular cloning in 1986 (37, 40, 57, 111). 
The human IL-6 gene has a length of approximately 5 kb and contains five exons. It 
maps to human chromosome 7p21-p14. Human IL-6 is synthesized as a precursor 
protein of 212 amino acids. The mature protein is composed of 185 amino acids, and 
is glycosylated at positions 73 and 172 (40). Monocytes express at least five different 
molecular forms of IL-6 with molecular masses of 21-28 kDa. They mainly differ by 
post-translational modifications such as glycosylation and phosphorylation (81). The 
murine gene maps to chromosome 5. The murine IL-6 precursor consists of 211 
amino acids with a signal sequence of 24 residues, resulting in a mature protein of 
187 amino acids. Murine and human IL-6 show 65% sequence homology at the DNA 
level and 42% homology at the protein level (103, 104).
IL-6 is a member of the subfamily of cytokines which also includes leukemia 
inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), oncostatin M, IL-11, and 
cardiotrophin-1 (CT-1), because of their functional redundancy, structural similarity, 
and sharing of a receptor subunit. The IL-6 receptor consists of an IL-6 binding site 
and a signal transducer, gp130, which is shared among the receptors of the IL-6 
related cytokine subfamily. This sharing of a receptor subunit is a general feature of 
cytokine receptors and provides the molecular basis for the functional redundancy of 
cytokines (51, 41). All known members of this IL-6 cytokine subfamily induce hepatic 
expression of acute phase proteins. Alternative names for IL-6 were interferon beta-2 
(IFNB2), B-cell stimulatory factor-2 (BSF2), hepatocyte stimulatory factor (HSF) and 
hybridoma growth factor (HGF), but since the 1988 conference "Regulation of the 
acute phase and immune responses: interleukin-6” these factors should all be 
referred to as IL-6 (2, 85, 104, OMIM #147620).
IL-6 is characterized by functional pleiotropy. It is involved in the immune 
response, various inflammatory reactions, hematopoiesis, and osteoporosis, and is 
produced by many different cell types. The main sources in vivo are stimulated 
monocytes, fibroblasts, and endothelial cells. Macrophages, T-cells and B-
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lymphocytes, granulocytes, smooth muscle cells, eosinophils, chondrocytes, 
osteoblasts, mast cells, glial cells, and keratinocytes also produce IL-6 after 
stimulation. Physiological stimuli for the synthesis of IL-6 are bacterial endotoxins, IL- 
1, TNF, platelet-derived growth factor (PDGF), and oncostatin M. IL-6 can also 
stimulate or inhibit its own synthesis, depending upon the cell type. High levels of IL- 
6 are detected in the synovial fluid of patients with rheumatoid arthritis (2, 50, 104).
Results from a number of studies, mainly in vitro, indicate that IL-6 may play 
an important role in the interaction between the immune system and the HPA axis. 
This cytokine is produced by the cells mentioned above and by cells in the 
hypothalamus (84, 88) and in the pituitary gland (89). Healthy human volunteers 
intravenously injected with a low dose of endotoxin from Gram-negative bacteria 
show a monophasic rise in the plasma concentrations of IL-6 peaking after 2 to 3 
hours (33, 102). Mouse and rat studies indicate that systemic administration of 
endotoxin is able to induce IL-6 gene transcription in many organs, including spleen, 
liver, lung, intestine and kidneys, with a maximum expression being detected 1 to 2 
hours post injection (61, 97). IL-6 has an inhibitory effect on the secretion of TNF and 
IL-1 (1, 83), and a stimulatory effect on glucocorticoid release by the adrenal gland 
(66, 80).
Although IL-6 is regarded as an important cytokine in the interaction between 
the immune system and the HPA axis, its role in vivo has not been established 
unequivocally. A new in vivo approach to study the role of IL-6 in infection induced 
HPA axis activation is to compare the corticosterone concentration in plasma of IL-6- 
deficient (IL-6-/-) and wild-type control (IL-6+/+) mice during infection. So far, only a 
few observations have been reported on corticosterone responses to LPS injection in 
IL-6-/- mice compared to those in IL-6+/+ mice (32, 52). The main conclusion from 
these observations was that IL-6 is not an important mediator in the LPS induced 
activation of the HPA axis. However, this result should be interpreted with caution as 
in both studies the corticosterone response was analyzed for only one dose of LPS 
and at only one time point. We expect that studies with different doses of LPS, 
combined with various infection models and multiple time points will help to elucidate 
the role of IL-6 in the inflammation induced HPA axis activation.
1.3.3 Corticotropin-releasing hormone
CRH is well known as the predominant regulator of the neuroendocrine and 
behavioural responses to stress (65). It plays a key role in the way the central 
nervous system controls the activity of the pituitary-adrenal axis (22).
The factor presently referred to as CRH was identified by in vitro experiments 
of Guillemin and Rosenberg (36) and of Saffran and Schally (79). They 
demonstrated that a factor from the hypothalamus was regulating the release of 
ACTH from the pituitary gland. They named this principle "corticotropin-releasing
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factor” or CRF. This factor was further characterized by Vale and colleagues (77, 99) 
as a 41 amino-acid peptide. Later on it was found that CRF not only functions as a 
neurotransmitter but also is released into the blood, and with its structural 
characterization the term "factor” was replaced by "hormone”. The precursor pre-pro- 
CRH contains a signal peptide, a motif conserved among all vertebrate CRH 
precursors, and the CRH peptide itself (53). The CRH sequence is highly conserved, 
with homology at the protein level ranging from 63% to 100% between vertebrate 
species. This strong conservation points to an early origin of the stress response 
during evolution (55). CRH belongs to the CRF superfamily which also includes the 
frog sauvagine, fish urotensin I, its mammalian counterpart urocortin (53, 105), and 
the diuretic peptide in insects (24). Vertebrate CRH has been characterized from fish 
(Catostomus commersoni) (59), an amphibian (Xenopus laevis) (90) and from 
several mammalian (human, rat, sheep, bovine) species (99, 77, 53).
CRH mRNA (45, 110) and CRH peptide (3, 82) are abundantly present in 
neurons of the paraventricular nucleus of the hypothalamus. In terrestrial vertebrates 
these parvocellular neuroendocrine neurons project on the median eminence (49) 
and release CRH into the portal circulation in response to stressors (4, 71, 99, 100). 
Upon arrival in the anterior pituitary, CRH binds to CRH receptors expressed on 
corticotropic cells (21, 109), and stimulates the synthesis (18) and release (76) of 
POMC-derived peptides such as ACTH from the anterior pituitary gland (64). The 
target of circulating ACTH is the adrenal cortex where it induces the biosynthesis 
and release of glucocorticoids, but also of mineralocorticoids and androgens (22). In 
fish, which do not have a median eminence, the CRH neurons directly innervate the 
pituitary gland where CRH is released (107).
The CRH gene is also expressed in a number of peripheral tissues, many of 
which are not directly related to the activity of the HPA axis. Immunoreactive CRH 
(ir-CRH) and CRH mRNA are present in the adrenal medulla, lymphocytes, 
pancreas, lung, liver, stomach and duodenum. Furthermore, CRH is expressed in 
human placenta and in a number of reproductive tissues, including ovaries and 
testes (65, 68, 92, 98). CRH is detectable in rat and human inflammatory sites, 
acting as a local autocrine or paracrine pro-inflammatory regulator (47). It has been 
shown that immunoneutralisation of local CRH in inflammatory tissue, in contrast to 
neutralisation of central CRH, attenuates the inflammatory response (47).
1.4 Infection models used in this thesis
In this thesis we used infections with different pathogens to compare the 
immune and the adrenal responses between IL-6-/- and IL-6+/+ mice. To mimic a 
bacterial infection in mice and in tilapia, administration of bacterial endotoxin was 
used. Background information on the infections used is given in this paragraph.
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The first infection model we used in mice was Candida albicans, a yeast 
infection that starts in the digestive system and spreads little by little to other parts of 
the body. The disseminated Candida infection is destructive for a variety of tissue 
and it impairs the functioning of the immune system, the spleen, the adrenal glands, 
the kidneys, lungs, liver and especially the brain and the nervous system. Candida 
yeast cells can become so massive and invasive that they transform in the fungal 
form, with very long, root-like structures. Penetration of the mucous lining of the 
gastrointestinal wall by Candida yeast cells can disrupt the protective barrier 
between the intestinal tract and the bloodstream, allowing many foreign and toxic 
substances to enter and contaminate the body systemically (58, 94).
In addition to C. albicans we used the Gram-negative pathogens Yersinia 
enterocolitica and Klebsiella pneumoniae, and moreover we administered endotoxin 
from Escherichia coli. Yersinia, Klebsiella, and Escherichia are genera of the family 
Enterobacteriaceae. Endotoxins are produced by Gram-negative bacteria and are 
released during division or death of the cells (34). Endotoxins mainly consist of lipid 
and polysaccharides, which led to the name lipopolysaccharide (LPS), of which the 
lipid component (lipid A) is anchored in the outer membrane of the bacteria, and the 
polysaccharide part is protruding into the extracellular space (75).
In tilapia, endotoxins from E. coli, as in mouse, and from Vibrio cholerae were 
used. Vibrio infections, caused by Gram-negative bacteria of the family 
Vibrionaceae, occur world wide in fish from marine and estuarine environments. The 
disease can cause significant mortality in fish culture facilities once an outbreak is in 
progress. Common names for Vibrio infections of fish include "red pest” (in eels), 
"salt-water furunculosis", "red boil", and "pike pest". Vibrio infections can spread 
rapidly when fish are confined in heavily stocked, commercial systems, and morbidity 
may reach 100% in affected facilities (35, 72). Humans can also be infected by Vibrio 
species, for instance via infected water or food (in particular fish).
1.5 Outline of this thesis
In the interaction between the immune system and the HPA axis, the cytokine 
IL-6 and the neuropeptide CRH are important mediators. So far, the role of IL-6 in 
infection induced HPA activation in mammals has not been established 
unequivocally, and little is known about the role of CRH in the infection induced 
stress response in fish. The research described in this thesis was focused on the 
role of IL-6 and CRH in the response to infectious agents in a mammalian and a 
teleost fish model, respectively. First, the responses of the immune system and the 
HPA axis to infection with micro-organisms and to injection with purified endotoxin 
were investigated in IL-6-/- an IL-6+/+ mice. Second, the involvement of the 
hypothalamic neuropeptide CRH in immune-neuroendocrine interactions was 
investigated in tilapia.
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The aim of the study described in CHAPTER 2 was to investigate the role of 
endogenous IL-6 in the defense against infection with the yeast C. albicans, and to 
establish whether activation of neutrophils mediates the beneficial effects of IL-6. We 
hypothesized that susceptibility to C. albicans in mice may be mediated through 
impaired neutrophil function. We determined the survival of IL-6-/- and IL-6+/+ mice 
after C. albicans infection and the fungal load in different organs. Furthermore, we 
investigated recruitment of neutrophils, the in vitro killing capacity of C. albicans by 
isolated neutrophils and macrophages, the ex vivo cytokine production by peritoneal 
macrophages, and the cytokine concentrations in blood during disseminated 
candidiasis.
CHAPTER 3 describes the results of Y. enterocolitica infection in IL-6-/- and 
IL-6+/+ mice. The host defense against infection with Y. enterocolitica critically 
depends on activated neutrophils as well as on the generation of T-helper cells. To 
address the involvement of IL-6 during infection with Y. enterocolitica we compared 
the course of infection in IL-6-/- mice to that in IL-6+/+ mice. We determined the 
mortality of mice after infection with Y. enterocolitica, as well as the generation of 
infection-associated neutrophilia and the bacterial outgrowth in liver, spleen, kidneys 
and mesenteric lymph nodes.
The aim of the study described in CHAPTER 4 was to investigate the role of 
endogenous IL-6 in a potentially lethal infection with K. pneumoniae. We examined 
the mortality of IL-6-/- and IL-6+/+ mice after infection with K. pneumoniae as well as 
bacterial outgrowth in several organs. To investigate the role of IL-6 in vivo in the 
activation of the HPA axis during bacterial sepsis, we studied the effect of 
administration of K. pneumoniae on plasma levels of corticosterone and the 
cytokines TNF and IL-1 in these mice.
Previous studies from our group demonstrated that administration of LPS in 
rodents induces the release of pro-inflammatory cytokines (TNF, IL-1, IL-6) and of 
ACTH and corticosterone, which indicates activation of the HPA axis (see thesis 
M.J.M. van der Meer, 1996). In CHAPTER 5 we examined the effects of 
intraperitoneal administration of LPS from E. coli on plasma corticosterone, TNF and 
IL-1 levels in IL-6-/- and IL-6+/+ mice. We also studied the involvement of IL-1 and 
TNF in the responses to LPS in IL-6-/- and IL-6+/+ mice by chronic infusion of 
recombinant human IL-1 receptor antagonist (IL-1ra), and by injection of anti-TNFa 
antibodies, respectively.
In CHAPTER 6 we considered the possibility that CRH has a species specific 
structure. Not only does CRH differ between mammalian and fish species, but also 
peptide differences among the teleosts may be notable, as teleost fishes represent 
the vertebrate group with the highest number of extant species. The neuroendocrine 
stress response in the teleosts may differ between species, as is concluded on the 
basis of differences in the dynamics of the cortisol response to stimulation of the HPI 
axis in the few fish studied so far (6). Therefore, the first aim of the study described 
in this chapter was to determine the precursor cDNA sequence of tilapia CRH. As
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knowledge of the function of CRH in teleosts is fragmentary, the second aim was to 
test the biological potency of synthetic tilapia CRH in a homologous teleost bioassay 
(i.e. tilapia pituitary tissue) and to compare its ACTH and a-MSH releasing activity 
with that of rat CRH.
CHAPTER 7 describes a study on CRH distribution after injection with LPS in 
tilapia. The study addressed the possible involvement of CRH in the communication 
between the immune and the neuroendocrine system. We examined the effects of 
injection of LPS preparations from E. coli and V. cholerae on the HPI axis in tilapia, 
during basal conditions and during confinement. Emphasis was placed on 
quantitative analysis of brain and pituitary CRH contents, and on the determination of 
plasma cortisol, glucose and chloride levels.
Finally, in CHAPTER 8 a summary is given of the results described in this 
thesis, and some general conclusions are presented.
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Abstract
Interleukin-6 (IL-6) is a multifunctional cytokine that regulates multiple aspects 
of the innate immune response. It has been recently shown that endogenous IL-6 is 
crucial for an efficient defense against severe infections with Gram-negative and 
Gram-positive bacteria. The aim of the present study was to investigate the role of 
endogenous IL-6 in the defense against infection with the yeast Candida albicans. 
During experimental candidemia, IL-6 deficient mice (IL-6-/-) had a decreased 
survival and an increased fungal load in their organs when compared with IL-6+/+ 
controls, despite increased plasma concentrations of tumor necrosis factor-a (TNF), 
interleukin-1 a (IL-1 a) and IL-1 p. IL-6-/- mice were not able to mount an efficient 
neutrophil response during the infection. When mice were rendered neutropenic by 
cyclophosphamide, neutropenic IL-6-/- mice were equally susceptible to C. albicans 
when compared to neutropenic IL-6+/+ mice, implying that neutrophils mediate the 
beneficial effect of endogenous IL-6. In conclusion, IL-6-/- mice are more susceptible 
to disseminated candidiasis, and the effect of IL-6 is most likely mediated by 
neutrophils.
Introduction
Acute disseminated candidiasis is a life-threatening disease which occurs 
predominantly in immunocompromised patients. Despite development of new 
antifungal drugs, mortality associated with disseminated candidiasis remains high 
(25), and additional therapies directed towards the augmentation of host defense 
mechanisms would be a rational approach. Therefore, a better understanding of the 
mechanisms responsible for the defense against an invasive Candida infection is 
required in order to develop strategies aimed at boosting the anti-candidal actions of 
the immune system.
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in the regulation of 
immune response and hematopoiesis (33). IL-6 is not produced under physiological 
conditions, but its synthesis is strongly upregulated during sepsis, and the circulating 
concentrations of IL-6 have been suggested to have a prognostic value for the 
outcome of the patients (7). Several experimental studies have addressed the role of 
endogenous IL-6 production during infections, with the effect of IL-6 neutralization 
being beneficial in some (29, 31), but not in all models (17). More useful information 
was obtained from experiments performed in genetically manipulated mice deficient 
in IL-6 (IL-6-/- mice). IL-6-/- mice have been shown to be highly susceptible to 
infections caused by Listeria monocytogenes (3), Escherichia coli (4), Streptococcus 
pneumoniae (36), Mycobacterium tuberculosis (14), and Toxoplasma gondii (32), 
suggesting an important role for endogenous IL-6 in the host defense against 
pathogenic microorganisms. However, the action of IL-6 is pathogen-specific, as IL-
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6-/- mice are resistant to infection caused by Leishmania major (20) or Chlamydia 
trachomatis (23).
Recent studies have suggested that IL-6 may also play a role during Candida 
albicans infection. Cell-wall components from C. albicans stimulate IL-6 production in 
vitro (2, 39), and elevated IL-6 concentrations have been detected during 
experimental infection with C. albicans (30). Moreover, Romani et al. have recently 
shown that IL-6-/- mice are more susceptible to infection with C. albicans, and this 
was suggested to be due to a Th2-biased response in the IL-6 deficient animals (27). 
However, it has become apparent from several studies performed during recent 
years that neutrophils are the main cellular component of the immune system 
responsible for the defense against C. albicans (11). The growth of C. albicans in 
vitro is inhibited by polymorphonuclear neutrophils (16), and mice rendered 
neutropenic are highly susceptible to disseminated candidiasis (37). Moreover, 
stimulation of neutrophil function by G-CSF (12) or proinflammatory cytokines such 
as TNF (6) or interferon-Y (10) improves the outcome of experimental infection with 
C. albicans. The role of IL-6 in the activation of neutrophils is less well understood, 
although studies performed in IL-6-/- mice suggested a defective neutrophil function 
in the absence of the cytokine (3, 4). It is therefore reasonable to hypothesize that, in 
mice lacking cytokines important for the activation of neutrophil function, such as 
possibly IL-6, the increased susceptibility to disseminated candidiasis may be 
mediated through impaired neutrophil function. The aim of the present study was to 
investigate the role of endogenous IL-6 for the infection with C. albicans, and to 
establish whether activation of neutrophils mediates the beneficial effects of IL-6.
Materials and Methods 
Animals.
Breeding pairs of the homozygous IL-6-/- and IL-6+/+ mice were obtained 
from Dr. M. Kopf (Max-Planck-Institut für Immunobiologie, Freiburg, Germany) (13). 
Standard safety and breeding protocols for transgenic mice were followed to produce 
a colony that was housed under specific pathogen-free conditions. Mice were kept 
under a 12/12 h dark/light cycle and were fed sterilized laboratory chow (Hope 
Farms, Woerden, The Netherlands) and acidified water ad libitum. Age and weight - 
matched healthy female mice (20-25 g, 6 to 8 weeks old) were used in the 
experiments.
C. albicans infection model.
C. albicans UC 820, a clinical isolate which has been well described 
previously (15) was used in all experiments. Mice were injected intravenously with C. 
albicans (104 - 106 colony forming units (CFU)/mouse) in a 100 ^l volume, as 
indicated. Survival was assessed daily for 30 days in groups of at least 20 animals.
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At the end of the observation period, the surviving mice were anesthetized with ether 
and killed by cervical dislocation. In addition, subgroups of 5 animals were killed on 
days 1 and 3 of infection, and blood was collected on EDTA for plasma cytokine 
concentration measurements. Circulating leukocytes were counted in a 
haemacytometer (Coulter Electronics, Mijdrecht, The Netherlands), and 
differentiation was assessed microscopically after Giemsa staining. To assess the 
outgrowth of the microorganisms, the liver, spleen and kidneys of the killed animals 
were removed aseptically, weighed, and homogenized in sterile saline using a tissue 
grinder. The number of viable Candida cells in the tissues was determined by plating 
serial dilutions on Sabouraud glucose agar plates as described previously (8). The 
CFU were counted after 24h of incubation at 37 °C, and expressed as log CFU/g of 
wet tissue.
To investigate the role of polymorphonuclear neutrophils (PMN) in Candida 
infection in IL-6-/- mice, groups of deficient and normal mice were rendered 
neutropenic by pre-treatment with cyclophosphamide (Bristol-Myers Squibb, Weesp, 
The Netherlands): 150 mg/kg was administered subcutaneously four days before 
infection, followed by 100 mg/kg one day before infection as well as 1, 3, 5, 7, and 9 
days after i.v. injection of 104 CFU C. albicans (9). This is a well-tested model of 
neutropenia, maintaining blood neutrophils at levels lower than 100/mm3 (9, 38). The 
outgrowth of the microorganisms in the organs and the survival of mice during 
disseminated candidiasis in neutropenic mice was investigated as described above.
Recruitment of neutrophils.
To investigate the recruitment of PMN at the site of Candida infection, groups 
of five IL-6+/+ mice and IL-6-/- controls were injected intraperitoneally with 107 CFU 
C. albicans. After 4h, peritoneal cells were collected in sterile saline containing 
0.38% sodium citrate, and the total cell number was counted in a haemacytometer. 
The percentage and the absolute numbers of neutrophils were determined in 
Giemsa-stained cytocentrifuge preparations (10).
Killing of C. albicans by neutrophils and macrophages.
Mice were injected intraperitoneally with 107 CFU C. albicans, and peritoneal 
neutrophils were collected 4h later and counted as described above. The cells were 
adjusted to 5 x 105/ml in RPMI 1640 in 10 ml silicone-coated tubes (Sherwood 
Medical, Ballymoney, N. Ireland). To assess the initial candidal load in the cells, 
representing the amounts of Candida phagocytosed by the neutrophils in vivo, a 100 
Ml sample was centrifuged (500g, 10 min). The supernatant containing the 
uningested microorganisms was discarded, the cells were washed twice in sterile 
phosphate buffered saline (PBS; pH 7.4), and lysis of the PMN was performed in 
water containing 0.01% bovine serum albumin (Sigma Chemical Co, St.Louis, MO). 
Serial dilutions of the suspension containing the intracellular yeasts were plated on 
Sabouraud agar plates, and the C. albicans were counted after 24h of incubation.
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Killing of C. albicans by PMN was assessed in the same cell suspension. A 
total of 2 ml of the cell suspension were incubated at 37 °C under slow continuous 
rotation. After 2h and 4h, a 100 M sample was taken from both IL-6-/- and IL-6+/+ 
neutrophils, cells were lysed, and C. albicans CFU were enumerated after 24h of 
culture on Sabouraud agar plates. The number of viable intracellular C. albicans 
colonies after each of the incubation periods represented the amounts of yeasts not 
killed by the cells. The percentage killed Candida was defined as ([CFU 
phagocytized - CFU after incubation]/CFU phagocytized) x 100.
Ex vivo cytokine production.
Resident peritoneal macrophages were harvested from non-infected IL-6-/- 
and IL-6+/+ mice. After centrifugation and washing, the cells were resuspended in 
RPMI 1640 containing 1 mM pyruvate, 2 mM L-glutamine, 100 ^g/ml gentamicin and 
2% fresh mouse plasma (culture medium). Cells were cultured in 96-well microtiter 
plates (Costar Corporation, Cambridge, MA) at 105 cells/well, in a final volume of 200 
Ml. The cells were stimulated with either 1 ng/ml lipopolysaccharide (LPS, E.coli 
serotype O55:B5, Sigma Chemical Corp, St. Louis, MO), or heat-killed (1h, 100 °C) 
C. albicans 107 CFU/ml. After 24h of incubation at 37 °C, the plates were centrifuged 
(500 g, 10 min), and the supernatant was collected and stored at -80 °C until 
cytokine assays were performed. To assess the cell-associated cytokines, 200 M of 
culture medium was added to the remaining cells, and the membranes were 
disrupted by three freeze-thaw cycles (18). The samples were stored at -80 °C until 
measurements were taken.
Cytokine assays.
IL-1 a, IL-1 p and TNF were determined by specific radioimmunoassays 
(detection limit 20 pg/ml), as previously described (21).
Statistical analysis.
The differences between groups were analyzed by Mann-Whitney U-test. 
Survival curves were analyzed by the Kaplan-Meyer log-rank test. For all 
comparisons, the level of significance between groups was set at p<0.05. All 
experiments were performed at least twice.
Results 
C. albicans infection model.
After i.v. infection of mice with 105 CFU C.albicans, 90% of the IL-6-/- mice 
died, whereas only 40% of the wild-type mice succumbed to infection (p<0.01) 
(Figure 1). Similarly, after an infection with 106 CFU C.albicans, the mortality of the
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knock-out mice was more rapid than that of normal mice (data not shown). The 
increased mortality of IL-6-/- mice was probably due to the increased numbers of 
C.albicans CFU in the organs, since the numbers of CFU on day 3 post-infection 
were significantly higher in the liver and kidneys of the IL-6-/- animals compared with 
IL-6+/+ controls (Figure 2).
Days of C. albicans infection 
Figure 1. Survival of mice after C. albicans infection.
Control IL-6+/+ mice (O) and knock-out IL-6-/- mice (• )  were infected intravenously with 1 x 10 CFU 
Candida per mouse. IL-6-/- mice had an increased mortality when compared with IL-6+/+ controls 
(p<0.01). No further deaths were recorded after day 22. Data represent results of 2 experiments 
consisting of 10 mice per group each.
After infection of mice with 105 CFU C.albicans, the number of circulating of 
PMN tended to be lower in the IL-6-/- than in IL-6+/+ mice on day 1 (6.2 + 2.7 x 109/l 
vs. 8.6 + 1.8 x 109/l, p=0.21) post-infection, and the difference reached statistical 
significance on day 3 after infection (3.8 + 1.5 x 109/l vs. 7.8 + 3.1 x 109/l, p<0.02).
When mice were infected with 105 CFU C.albicans, TNF and IL-1 a 
concentrations in the circulation of IL-6-/- mice were higher than those in IL-6+/+ 
mice, especially on day 3 after the infection (Figure 3). A similar trend was observed 
on day 1 of infection with 106 CFU C.albicans for both TNF (448 + 200 pg/ml in IL-6- 
/- vs. 302 + 146 pg/ml in IL-6+/+ mice, p=0.17) and IL-1 a (74 + 49 pg/ml in IL-6-/- vs. 
24 + 9 pg/ml in IL-6+/+ mice, p<0.03). Plasma IL-1 p concentrations were 
undetectable in most of the samples, and did not differ between the experimental 
groups (data not shown).
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Figure 2. Outgrowth of C. albicans in the organs.
Control IL-6+/+ mice (open bars) and knock-out IL-6-/- mice (hatched bars) were infected 
intravenously with 1x105 CFU Candida per mouse. On day 1 (Panel A) and 3 (Panel B) of infection, 
subgroups of mice were sacrificed and the growth of C. albicans in the liver, spleen and kidneys was 
assessed. Data represent mean + SD of 3 experiments consisting of 5 mice per group each. *p<0.05
Polymorphonuclear neutrophils are the most important cells in the defense 
against C. albicans, and neutropenic mice are more susceptible to disseminated 
candidiasis (37). To investigate the role of neutrophils in the IL-6-mediated 
protection, groups of IL-6-/- and IL-6+/+ mice were rendered neutropenic and 
infected with 105 CFU C. albicans. As shown in Table 1, the outgrowth of Candida in 
the organs of neutropenic knock-out or control mice did not differ, suggesting that the 
beneficial effects of endogenous IL-6 during systemic candidiasis are mediated 
through neutrophils.
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Figure 3. Circulating cytokine concentrations during disseminated candidiasis.
After infection of IL-6+/+ (O) and IL-6-/- ( • )  mice with 1x10 CFU Candida per mouse, subgroups of 
mice were sacrificed and the circulating cytokines measured by specific radioimmunoassays. On day 
3 of infection, IL-1 a plasma concentration was significantly higher in IL-6-/- than in IL-6+/+ mice 
(Panel A). A similar tendency for higher levels of TNF in IL-6-/- mice was also observed on day 1 and
3 of infection (Panel B).Data represent mean + SD of 2 experiments consisting of 5 mice per group 
each. *p<0.05
Table 1. The outgrowth of C. albicans in the organs of neutropenic animals.
C. albicans (log CFU/gram of tissue)
Mouse strain Liver Spleen Kidney
IL-6+/+ 4.5 + 0.2 5.0 + 0.2 5.7 + 0.2
IL-6-/- 4.7 + 0.2 5.0 + 0.2 5.9 + 0.4
IL-6-/- and IL-6+/+ mice were rendered neutropenic by repeated cyclophosphamide administration, 
and then infected with 105 CFU C. albicans/mouse. No differences between the outgrowth of the 
microorganisms in the organs of IL-6-/- and IL-6+/+ mice were apparent on day 3 of infection. Data 
represent mean + SD of two experiments consisting of five mice/group each.
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Ex-vivo cytokine production.
To test whether the differences in plasma cytokine concentrations during 
infection were solely due to differencies in fungal load in the IL-6-/- and IL-6+/+ mice, 
or in the cytokine production capacity of individual cells of the two mouse strains, 
resident peritoneal macrophages from both mouse strains were stimulated with 1 
ng/ml LPS or 107 CFU heat-killed C. albicans in vitro for 24h. Macrophages obtained 
from uninfected IL-6-/- mice synthesized significantly larger amounts of cell- 
associated IL-1 a than macrophages of IL-6+/+ animals did (Figure 4). It is known 
that 90% of the IL-1 a synthesized is cell-associated (5). Although not significant, a 
similar trend was observed for the release of TNF in the supernatant (p=0.07, Figure 
4), whereas the production of IL-1 p was very low and did not differ between the two 
mouse strains (data not shown).
Recruitment of polymorphonuclear neutrophils.
To investigate the recruitment of neutrophils at the site of a C. albicans 
infection, groups of IL-6-/- and IL-6+/+ mice were infected intraperitoneally with 107 
CFU C. albicans, and exudate peritoneal neutrophils were harvested and counted 4h 
later. The recruitment of neutrophils in the peritoneal cavity of IL-6-/- mice (11.8 + 1.0 
x 106 per mouse) was significantly reduced compared with that of IL-6+/+ mice (15.4 
+ 1.2 x 106 per mouse; p<0.02).
Table 2. Intracellular killing of C. albicans by neutrophils in vitro.
Mouse strain
Percentage of C. albicans killed intracellularly
After 2 h After 4 h
IL-6+/+ 47 + 13 67 + 6
IL-6-/- 39 + 8 55 + 5
Peritoneal neutrophils from knock-out and control mice were harvested 4h after intraperitoneal 
injection of 107 CFU C. albicans/mouse. Before incubation and after 2 and 4 h incubation at 37°C, 
samples of cells were taken and lysed, and the percentage of intracellular Candida assessed. No 
differences between the killing of the microorganisms by the neutrophils of IL-6-/- and IL-6+/+ mice 
were found. Data represent mean + SD of two experiments consisting of five mice/group each.
Killing of C. albicans by neutrophils in vitro.
Previous studies performed in IL-6-/- mice suggested a defective neutrophil 
function in the absence of this cytokine (3, 4). However, despite the lack of IL-6, 
neutrophils of IL-6-/- and IL-6+/+ mice were equally potent to kill C.albicans (Table 
2 ).
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Figure 4. In vitro cytokine production.
Resident peritoneal macrophages from IL-6+/+ and IL-6-/- mice were harvested and stimulated in vitro 
with either culture medium (CM), LPS (1 ng/ml) or heat-killed C. albicans (107 CFU/ml). Macrophages 
of IL-6-/- mice (hatched bars) stimulated with C. albicans produced significantly more cell-associated 
IL-1 a when compared with macrophages of IL-6+/+ mice (open bars) (Panel A). A trend towards 
increased TNF production by macrophages of IL-6-/- mice compared to control IL-6+/+ macrophages 
was also apparent (Panel B). Data represent mean + SD of 2 experiments consisting of 5 mice per 
group each. *p<0.05.
Discussion
In the present study it is shown that IL-6-/- mice are highly susceptible to a 
systemic infection with C. albicans. This phenomenon can be explained by an 
increased fungal outgrowth in the organs, despite the higher production of protective
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proinflammatory cytokines such as TNF and IL-1 a. Experiments performed in 
granulocytopenic IL-6+/+ and IL-6-/- mice demonstrate that neutrophils are the main 
mediators of the effects of endogenous IL-6. Reduced numbers of circulating 
neutrophils during infection and a defective recruitment of neutrophils at the site of 
tissue infection may be at least in part responsible for the blunted immune response 
against Candida in the IL-6-/- mice.
It has been recently demonstrated that endogenous IL-6 is important for a 
proper activation of the host defense during infections with Listeria monocytogenes 
(3), Escherichia coli (4), Streptococcus pneumoniae (36), Mycobacterium 
tuberculosis (14) and Toxoplasma gondii (32). It has been suggested that the 
deleterious consequences of IL-6 deficiency are exerted either through defective 
neutrophil function (3), or biased Th2 cytokine response during infection (14, 32). 
Because both these mechanisms play a role during disseminated candidiasis, we 
investigated the susceptibility of IL-6-/- mice to C. albicans infection. The IL-6 
deficient mice were significantly more susceptible to disseminated candidiasis than 
control mice, and this is in line with a recent study of Romani et al. reporting similar 
results (27). However, it is important to underline that these effects of IL-6 during 
infection are neither non-specific nor independent of the type of infection, as IL-6-/- 
mice are resistant to infection with Leishmania major (20) and Chlamydia 
trachomatis (23).
Little is known about the mechanisms responsible for the increased 
susceptibility of IL-6-/- mice to infection. Romani et al. have suggested that the 
susceptibility of IL-6-/- mice to infection with C. albicans could be due to a biased 
Th2 response in the IL-6-/- mice, since these mice produce lower amounts of IL-12 
and more IL-10 than controls (27). Although several studies have underlined the 
involvement of a Th1/Th2 imbalance in the increased susceptibility to C.albicans 
infection (28), with Th1-derived cytokines such as IFNy having a protective role in 
disseminated candidiasis (10), as has neutralization of Th2-derived cytokines (24, 
26), our data in neutropenic IL-6-/- mice suggest that neutrophils are likely to be the 
dominant protective mechanism through which IL-6 exerts its beneficial effects. This 
is in agreement with data showing that either endogenous (1) or recombinant (27) IL-
6, as well as molecules that induce IL-6 (34), are able to enhance the candidacidal 
activity of neutrophils.
An impaired recruitment of neutrophils at the site of infection has been a major 
factor for the increased susceptibility to disseminated candidiasis of knock-out mice 
deficient in both TNF and lymphotoxin-a (22). Likewise, the recruitment of 
neutrophils in the peritoneal cavity of IL-6-/- after C. albicans infection has been 
significantly lower than that in IL-6+/+ control mice, and this may represent an 
important mechanism for the decreased resistance to disseminated candidiasis in IL- 
6-/- mice. In contrast, the killing mechanisms of neutrophils of IL-6-/- mice against 
Candida are intact. In line with these data, similar killing of Candida blastospores 
was reported for neutrophils and macrophages of TNF-/- mice (19).
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The IL-6-/- mice showed an increased production of the proinflammatory 
cytokines TNF and IL-1 a, both in vivo and in vitro. This increased cytokine 
production is probably due to the lack of the negative feed-back mechanism 
represented by IL-6 on the production of proinflammatory cytokines (33). Although 
both TNF and IL-1 have been shown to have beneficial effects for the defense 
against C. albicans (19, 30, 35), their increased concentrations in the IL-6-/- mice did 
not seem to be sufficient to ensure protection against the infection. This suggests 
that IL-6 has important immunostimulatory activities of its own, and these effects 
cannot be compensated by redundant cytokines such as TNF and IL-1.
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CHAPTER 3
IL-6-deficient mice are highly susceptible 
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Abstract
It has been shown that interleukin-6 deficient (IL-6-/-) mice are more 
susceptible to infection with various micro-organisms (Gram-negative and Gram­
positive bacteria and Candida albicans) when compared to control (IL-6+/+) mice. 
The aim of the present study was to investigate the role of endogenous interleukin-6 
in the generation of infection-associated neutrophilia during the defense against the 
Gram-negative infection with Yersinia enterocolitica. Infection of IL-6-/- mice with Y. 
enterocolitica was characterized by an increased mortality as compared to IL-6+/+ 
mice. However, in contrast to findings in other models of infections, Y. enterocolitica 
infected IL-6-/- mice were capable of developing a normal peripheral neutrophilia. 
Despite the increased susceptibility to infection these mice did not harbor more 
bacteria in spleen, liver, kidneys or mesenteric lymph nodes when compared to IL- 
6+/+ mice, indicating a functional neutrophilia in IL-6-/- mice. Therefore, the lack of a 
neutrophil response does not seem to be an intrinsic characteristic of IL-6-/- mice, 
but rather depends on the pathogen involved in the infection.
Introduction
The pleiotropic cytokine interleukin-6 (IL-6) regulates various aspects of the 
immune response and plays an important role during infection (11). Apart from 
induction of the hepatic acute phase response, IL-6 is involved in hematopoiesis and 
priming of neutrophils (innate immune response) as well as in T- and B-cell 
differentiation (acquired immune response). The construction of mice with a 
disrupted IL-6 gene (6) has permitted more in-depth studies addressing the 
involvement of IL-6 during infection. IL-6-/- mice are more susceptible to infection 
with various micro-organisms, including Listeria monocytogenes (4), Helicobacter 
felis (2), Escherichia coli (5), Streptococcus pneumoniae (8), Klebsiella pneumoniae 
(10) and C. albicans (7, 9). Increased susceptibility of IL-6-/- mice has been 
correlated with an enhanced colony count of micro-organisms in their organs at 
autopsy, and has been assumed to result from the observed inefficient infection- 
associated neutrophilia. In addition, an impaired T-cell-dependent antibody response 
as well as reduced cytotoxic T-cell activity against vesicular stomatitis virus has been 
demonstrated (6). Furthermore, during C. albicans infection impaired CD4+ T helper 
cell 1 (TH1 cell) development has been observed in these mice (7).
Host defense against infection with Y. enterocolitica critically depends on 
neutrophils (3) as well as on the generation of TH1 cells (1). To address the 
involvement of endogenous IL-6 in the generation of infection-associated 
neutrophilia during infection with Y. enterocolitica we compared the course of 
infection in IL-6-/- mice to that in IL-6+/+ mice.
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Materials and Methods
Mice
Breeding pairs of IL-6-/- and IL-6+/+ mice (C57BI/6 x 129Sv hybrid genetic 
background) were a gift from M. Kopf (Basel Institute for Immunology, Basel, 
Switzerland) and were bred under specific pathogen free conditions in the Central 
Animal Laboratory of the Nijmegen University. Mice were housed in plastic cages 
and received water and food ad libitum. In this study only male mice were used.
Bacteria
Yersinia enterocolitica serotype O:8WA (ATCC strain 9610) was used in all 
experiments. This strain contains the 70 kb virulence plasmid. Bacterial stocks were 
kept in the freezer and one day before infection bacteria were inoculated in Brain 
Heart Infusion broth (BHI) and grown overnight at 26°C. Bacteria were then 
inoculated in fresh BHI and grown for another 3 hours at 37°C.
Infection
After washing, bacterial solutions of the appropriate concentrations were 
made in phosphate buffered saline (PBS). The amount of inoculated viable bacterial 
cells was verified by plating on Columbia blood agar plates. Infections were 
performed by injection of 0.2 ml bacterial suspension intravenously or per gavage as 
indicated. For survival studies mortality of mice was scored twice a day. For 
determination of Y. enterocolitica colony counts in organs, mice were sacrificed 48 
hours after infection. Liver, spleen, kidneys and mesenteric lymph nodes were 
collected, weighed, and homogenized in 1 ml PBS. Serial dilutions were plated on 
Columbia blood agar and on selective CIN (Cefsulodin-Irgasan-Novobiocin, Oxoid, 
Basingstoke, UK) plates. Colonies were counted after 48 hours of incubation.
Blood analysis
For determination of neutrophilia, mice were bled by orbita punction 24 hours 
after infection, and the blood was collected in EDTA containing tubes. An aliquot was 
taken and the cells were lysed whereafter the nuclei were counted in a Coulter 
Counter (Coulter Electronics Limited, Luton, UK) giving the total number of 
leucocytes per volume blood. Smears were made to determine the percentage 
neutrophils, and the amount of neutrophils per volume blood was calculated.
Statistics
Survival data were analyzed using the Kaplan-Meyer log rank test. 
Differences in outgrowth of the micro-organisms from organs and blood, and for 
recruitment of neutrophils, were analyzed using the Mann-Whitney U test. 
Differences were considered significant at P<0.05. The statistical analysis package 
SPSS version 6.1.3 (SPSS, Gorinchem, The Netherlands) was used.
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Hours of Y. enterocolitica infection
Figure 1. Survival of IL-6-/- (■,▲) and IL-6+/+ (D ,A ) mice after intravenous infection 
with 5x104 (■ ,□ ) CFU or 5x105 (A ,A ) CFU of Y. enterocolitica bacteria (6 mice per 
group).
Results 
Susceptibility of IL-6-/- mice to Y. enterocolitica compared to IL-6+/+ mice
To determine whether IL-6-/- mice are impaired in their mucosal immune 
response various doses of Y. enterocolitica were given per gavage. Even the highest
°
dose of 5x10° bacteria per mouse was insufficient to establish an infection and IL-6- 
/- as well as IL-6+/+ mice survived for more than two weeks. However, when the 
infection was given intravenously mice of both groups became progressively ill and 
died depending on the dose. Relatively high doses of 5x104, 5x105 or 2x106 bacteria 
per mouse resulted in death of all mice within one week. In all experiments IL-6-/- 
mice died sooner than IL-6+/+ mice. Figure 1 depicts the survival curves of a typical 
experiment in which groups of 6 mice were infected and followed for survival.
2 3Lowering the doses to 50, 5x102 and 5x103 bacteria/mouse enabled us to determine 
LD50 values for IL-6-/- as well as IL-6+/+ mice. Mice were followed for 21 days and 
survival was scored (Figure 2). No deaths occured after day 14. The LD50 for IL-6-/- 
mice was determined as 50 CFU whereas for IL-6+/+ mice it was 5x103 CFU.
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Days of Y. enterocolitica infection
Figure 2. Determination of LD50: IL-6-/- (B ,A ,* )  and IL-6+/+ (D ,A ,0 )  mice were 
infected intravenously with 50 CFU (■ ,□ ), 500 CFU (A ,A ), or 5000 CFU ( * , 0 )  of Y. 
enterocolitica bacteria (6-8 mice per group). Mice were followed for 21 days and 
survival was scored twice a day. No deaths occurred after day 14.
Bacterial outgrowth in liver, spleen, kidneys and mesenteric lymph nodes
To determine whether IL-6-/- mice had a reduced capability of bacterial killing 
as described for other infections, groups of IL-6-/- and IL-6+/+ mice (n=10 per 
group) were sacrificed 48 hours after infection with 50, 5x102 or 5x103 CFU and the 
colony count of bacteria in liver, spleen, kidneys and mesenteric lymph nodes were 
determined. Blood samples (100 ^l) were taken from a number of the mice of both 
groups 2 hours after infection. No bacteria could be cultured from these blood 
samples and thus within 2 hours after intravenous infection all bacteria appeared to 
be cleared from the bloodstream. Kidneys and mesenteric lymph nodes did not 
contain live bacteria. In respect to the amount of viable bacteria in liver and spleen 
no significant differences were found between IL-6-/- and IL-6+/+ mice infected with
50 or 5x102 CFU. Only marginally more bacteria were found in the spleen of IL-6+/+ 
mice when the infective dose was increased to 5x103 CFU (P = 0.03), but no 
differences were found in the livers.
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Development of infection-associated neutrophilia
Since no or only marginal differences were found in the number of bacteria in 
spleen and liver of Y. enterocolitica infected IL-6-/- and IL-6+/+ mice we compared 
the development of infection-associated neutrophilia in these mice. Groups of 5 mice 
were bled 24 hours after infection with 5x103 or 5x104 CFU and the number of 
neutrophils per ml blood was determined. Peripheral neutrophil numbers before 
infection did not differ significantly between both mouse strains (Figure 3, P = 0.11). 
IL-6-/- mice developed levels of neutrophilia comparable to IL-6+/+ mice after 
infection with 5x103 as well as 5x104 bacteria (P = 0.16 and P = 0.50 respectively). 
IL-6+/+ and IL-6-/- mice had the same total white blood cell counts before and 24 
hours after infection. The increase in neutrophil numbers was accompanied by a 
decrease in the amount of lymphocytes (results not shown).
Figure 3. Peripheral neutrophilia in IL-6+/+ mice (open bars) and IL-6-/- mice (hatched 
bars) 24 hours after intravenous infection with 5x103 CFU or 5x104 CFU of Y. 
enterocolitica bacteria.
Discussion
This study demonstrates that IL-6-/- mice are capable of developing normal 
neutrophilia in response to infection with Y. enterocolitica. This is in contrast to 
observations made in IL-6-/- mice infected with either L. monocytogenes (4), H. felis 
(2), E. coli (5), K. pneumoniae (10) or C. albicans (7, 9). In these infection models 
the reduced neutrophilia is considered to be an explanation for the increased 
amounts of micro-organisms in liver and/or spleen, and consequently for the 
increased mortality. Injection of recombinant IL-6 in IL-6-/- mice induced neutrophilia 
and restored neutrophil effector function characterized by a reduced colony count of 
micro-organisms in their tissues (4). When mice were rendered neutropenic by
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cyclophosphamide, neutropenic IL-6+/+ mice were equally susceptible to C. albicans 
compared to neutropenic IL-6-/- mice, implying that neutrophils mediate the 
beneficial effect of endogenous IL-6 (9). In the present study no differences in 
neutrophil counts were observed between Y. enterocolitica infected IL-6-/- and IL- 
6+/+ mice. Therefore, it must be concluded that IL-6-/- mice are not inevitably 
impaired in the development of infection-associated neutrophilia, but that this 
capability depends on the infective agent. Moreover, no differences are found in the 
amount of bacteria in spleen and liver of IL-6-/- and IL-6+/+ mice, suggesting a 
normal neutrophil function in our mice. Despite the earlier observations that mice 
critically depend on neutrophils in their defense against Y. enterocolitica (3), our IL-6- 
/- mice are more susceptible to infection than IL-6+/+ mice, indicating that other 
factors in addition to neutrophils are involved in the defense against Y. enterocolitica.
Autenrieth et al. (1) described the involvement of CD4+ TH1 cell and cytotoxic 
T-cells in mouse models of Y. enterocolitica infection. Because IL-6 acts as a potent 
costimulatory signal in CD4+ T-cell activation and promotes both cytotoxic T-cell 
proliferation and NK function (11), IL-6-/- mice may be impaired in their ability to 
mount a specific cellular immune response. This is supported by the observation that 
during C. albicans infection IL-6-/- mice are impaired in their CD4+ TH1 cell 
development (7). However, lack of the generation of cytotoxic T-cells or NK cells is 
also expected to result in an enhanced bacterial load. We observed no differences 
between the colony counts of Y. enterocolitica in organs of IL-6-/- and IL-6+/+ mice. 
Whether or not the aforementioned cell types are crucially involved in the defense 
against Y. enterocolitica infection in our mouse model remains to be investigated.
The hypothesis now arises that IL-6-/- mice may be more sensitive to bacterial 
products such as lipopolysaccharide (LPS). However, increased susceptibility to Y. 
enterocolitica derived LPS is not very likely since mortality of IL-6-/- mice after 
injection with various doses of bacterial LPS has been found not to be different from 
that of IL-6+/+ mice (5, 10). The observation that the mortality period with the Y. 
enterocolitica infection runs from 2 days to 14 days (depending on the infective dose) 
with a consistent difference between survival of IL-6-/- and IL-6+/+ mice, indicates 
that the cause of death does not solely result from the relatively short period (< 2 
hours) of infection-associated sepsis. It remains to be investigated whether IL-6-/- 
and IL-6+/+ mice are equally susceptible to injection with LPS from a variety of 
Gram-negative bacteria.
A remarkable observation remains that IL-6-/- mice in the present study are 
capable of an infection-associated peripheral neutrophil response comparable to that 
found in IL-6+/+ mice. If neutrophils are indeed involved in the defense against Y. 
enterocolitica this may very well explain the absence of differences in the bacterial 
load between the two types of mice, but this does not explain differences in survival. 
The factors responsible for the induction of neutrophilia in IL-6-/- mice remain to be 
elucidated as does the basis for the enhanced susceptibility to infection with Y. 
enterocolitica.
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Abstract
During bacterial infections both the immune system and the hypothalamus- 
pituitary-adrenal (HPA) axis are activated. The role of IL-6 in the activation of the 
HPA axis during bacterial sepsis is not fully understood. The aim of the present study 
was to investigate the role of endogenous IL-6 in a potentially lethal infection with 
Klebsiella pneumoniae and the concomitant activation of the HPA axis. We 
examined the mortality of IL-6-/- and IL-6+/+ mice after intravenous (i.v.) infection 
with K. pneumoniae as well as the bacterial outgrowth in several organs. 
Subsequently, the influence of endogenous IL-6 on the effect of i.v. administration of 
K. pneumoniae on the plasma levels of corticosterone and the pro-inflammatory 
cytokines TNFa and IL-1 a was investigated in these mice. The present study 
demonstrates that IL-6-/- mice are more susceptible than IL-6+/+ mice to a systemic 
Gram-negative infection with K. pneumoniae, leading to increased outgrowth of 
microorganisms in the organs of the mice. Moreover, this infection is associated with 
a reduced adrenal response in IL-6-/- mice. We conclude that IL-6-/- mice are more 
susceptible to Gram-negative bacterial infections, which is mainly due to an impaired 
recruitment of granulocytes to the site of infection in the absence of IL-6. 
Furthermore, the reduced adrenal response may be an explanation for the strong 
inflammatory response with higher TNFa plasma levels in IL-6-/- mice.
Introduction
During bacterial infections both the immune system and the hypothalamus- 
pituitary-adrenal (HPA) axis are activated (6, 31). Sepsis due to infection with Gram­
negative bacteria is often related to high circulating levels of pro-inflammatory 
cytokines, such as tumor necrosis factor a (TNFa), interleukin-1 a (IL-1 a) and 
interleukin-6 (IL-6) (13, 19). It has been shown that lipopolysaccharide (LPS) from 
Gram-negative bacterial cell walls induces the release of these cytokines (12, 29, 
37). Furthermore, LPS induces an increase in plasma levels of adrenocorticotropic 
hormone (ACTH) and corticosterone, which is characteristic of an activated HPA axis 
(10, 12, 26). Cytokines and glucocorticoid hormones are believed to integrate an 
immuno-regulatory feedback circuit: TNF, IL-1 and IL-6 stimulate ACTH and 
corticosterone release (2, 16, 21, 30, 33), whereas glucocorticoids suppress immune 
cell functions and production of cytokines, thereby protecting the organism against a 
harmful overshoot of immune reactions (2, 9, 11, 14, 32).
IL-6 reportedly plays a pivotal role in the interaction between the immune 
system and the HPA axis (23). This pleiotropic cytokine is produced both by immune 
cells and by cells in endocrine tissues (20). IL-6 has an inhibitory effect on the 
secretion of TNF and IL-1 (1, 29), and a direct stimulatory effect on glucocorticoid 
release by the adrenal gland (24, 28).
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Evidence for a protective role of IL-6 during infection was obtained by 
investigating mice that are genetically deficient in the production of IL-6 (17). IL-6- 
deficient (IL-6-/-) mice have been shown to be more susceptible than wild-type (IL- 
6+/+) control mice to infections caused by a variety of microorganisms (7, 8, 18, 27, 
34, 35). In a previous study, we have shown that IL-6-/- mice were not able to mount 
an efficient neutrophil response during the infection with Candida albicans, 
explaining why the IL-6-/- mice are more susceptible to disseminated candidiasis 
(35).
The role of IL-6 in the activation of the HPA axis during bacterial sepsis is not 
fully understood. The aim of the present study was to investigate the role of 
endogenous IL-6 in a potentially lethal infection with K. pneumoniae and the 
concomitant activation of the HPA axis. We examined the mortality of IL-6-/- and IL- 
6+/+ mice after an intravenous (i.v.) infection with K. pneumoniae, as well as the 
bacterial outgrowth in several organs, and the recruitment of polymorphonuclear 
neutrophils (PMN) to the site of Klebsiella injection. Subsequently, the influence of 
endogenous IL-6 on the effect of i.v. administration of K. pneumoniae on the plasma 
levels of corticosterone, and of the pro-inflammatory cytokines TNFa and IL-1 a, was 
investigated in these mice.
Materials and Methods 
Animals
Breeding pairs from the mixed (C57Bl/6 x 129/Sv) F2 generation of both IL-6- 
deficient (IL-6-/-) and wild-type control (IL-6+/+) mice were obtained from the Max- 
Planck-Institut für Immunbiologie, Freiburg, Germany (17). Homozygous IL-6-/- and 
IL-6+/+ mice were housed under specific pathogen free conditions (according to 
FELASA recommendations (25)) at the Central Animal Laboratory of the University 
of Nijmegen.
Only healthy male offspring of 10-16 weeks old, weighing 20-30 grams, were 
used. Mice were housed in groups of 4 to 10 animals per cage. Mice were kept 
under a 12/12 hours dark/light cycle (lights on at 0700 h) and received acidified 
water and standard food (Hope Farms, Woerden, The Netherlands) ad libitum.
Materials
Klebsiella pneumoniae (ATCC 43816), a strain that can produce lethal 
infection in mice (1), was cultured overnight, and suspensions were washed in sterile 
physiological saline (0.9% NaCl) and subsequently diluted to the appropriate 
concentration immediately before use. Lipopolysaccharide (LPS E. coli 0111:B4) 
was purchased from Sigma (St. Louis, MO).
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Experimental protocols
Lethal K. pneumoniae infection model and lethal endotoxemia model
K. pneumoniae were injected intravenously (i.v., 100 Ml) into the retro-orbital 
plexus of IL-6-/- and IL-6+/+ mice under mild ether anesthesia. Doses of either 102, 
103 or 104 colony forming units (CFU) were injected at 10 a.m. Injections with sterile 
physiological saline were used as controls. Survival was assessed twice daily in 4 to 
11 IL-6-/- or IL-6+/+ mice per group for 14 days. Each experiment was performed 3 
or 4 times.
LPS, dissolved in physiological saline, was injected intraperitoneally (i.p., 200 
Ml) at 9 a.m. in doses of 250, 500, 1000 or 2000 Mg per mouse. Survival was 
assessed daily in 2 to 7 animals per group for 14 days. Each experiment was 
performed 2 to 5 times.
Outgrowth of K. pneumoniae in organs and blood
A K. pneumoniae suspension of 102 CFU was injected i.v. (100 Ml) into IL-6-/- 
and IL-6+/+ mice (8 or 9 mice per group). After 24 hours mice were anaesthetized 
with ether, a blood sample was taken from the orbital plexus, and organs (liver, lung, 
spleen, kidney) were removed aseptically, cleared of adhering fat, weighed, and 
homogenized in sterile physiological saline in a tissue grinder. Outgrowth of the 
microorganisms in the organs and blood of the animals was quantified by plating 
serial dilutions of the homogenized tissues or blood samples on sheep blood agar 
plates, and counting the number of CFU after overnight incubation at 37 °C.
Recruitment of neutrophils
To investigate the recruitment of PMN at the site of Klebsiella infection, 
groups of four IL-6-/- and IL-6+/+ mice were injected intraperitoneally with 107 
CFU/ml heat-killed K. pneumoniae. Before injection and 4, 8, and 24 hours 
thereafter, peritoneal cells were collected in sterile saline containing 0.38% sodium 
citrate, and the total cell number was counted. The percentage and the absolute 
number of neutrophils were determined in Giemsa-stained cytocentrifuge 
preparations (35).
Plasma glucocorticoid and cytokine levels during K. pneumoniae infection
At 4, 8 or 24 hours after i.v. injection of K. pneumoniae, mice were 
decapitated to obtain trunk blood for determination of plasma corticosterone, TNFa 
and IL-1 a levels (7 to 11 mice per group). Blood was collected on ice in (K3) EDTA 
Monoject Samplette whole blood collector tubes (Sherwood Medical, St.Louis, MO) 
to which 250 KIE aprotinine (25 Ml, Trasylol, Bayer AG, Leverkusen, Germany) was 
added. Collected blood was centrifuged for 10 minutes at 1,500x g (4 °C), and 
plasma was separated and stored at -20 °C until assayed.
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Corticosterone and cytokine assays
Corticosterone levels were determined by radioimmunoassay (RIA) after 
extraction by dichloromethane as described before (30). Mouse TNFa and IL-1 a 
antigen values were measured by specific RIAs (22). The detection limits of the 
cytokine assays were 0.04 and 0.02 ng/ml, respectively.
Statistical Analysis
Survival data were analyzed using the Kaplan-Meyer log rank test. 
Differences in outgrowth of the microorganisms from organs and blood, and for 
recruitment of neutrophils, were analyzed using the Mann-Whitney U test. 
Differences were considered significant at P<0.05. For blood sample data of 
corticosterone, TNFa and IL-1, a 2-Way analysis of variance (2-Way ANOVA) was 
performed where appropriate. Further comparisons of group means by 1-Way 
ANOVA were carried out, using Bonferroni corrections to maintain the overall level of 
significance at P<0.05. The statistical analysis package SPSS version 6.1.3 (SPSS, 
Gorinchem, The Netherlands) was used.
D ays d u rin g  K. p n e u m o n i a e  in fec tio n
Figure 1. Survival of IL-6-deficient (IL-6-/-) and wild-type (IL-6+/+) control mice after i.v. 
injection with K. pneumoniae.
IL-6-/- mice ( • )  were more susceptible than IL-6+/+ mice (O) to infection with 10 CFU of K. 
pneumoniae (27-28 mice per group). No mice died 14 days or later after the injection. P<0.0001, 
Kaplan-Meyer log rank test.
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Results
Lethal K. pneumoniae infection model
Survival after i.v. infection with K. pneumoniae was significantly lower in IL-6-/- 
mice when compared to IL-6+/+ mice (Figure 1). After injection of 102 CFU, only 4% 
of the IL-6-/- mice survived, whereas survival of IL-6+/+ mice was 43% (P<0.0001). 
Mortality in IL-6-/- mice was 100% within 2 or 3 days after injection of 104 CFU (data 
not shown). Of the IL-6+/+ mice, however, 27% survived after injection of 104 CFU 
(P<0.0001).
Lethal endotoxemia model
Survival after 14 days did not differ significantly between IL-6-/- mice and IL- 
6+/+ mice after i.p. injection of 0.25 mg to 2 mg LPS (Figure 2).
LPS (mg/mouse)
Figure 2. Survival of IL-6-/- mice and IL-6+/+ mice after i.p. injection of LPS.
Survival after 14 days was not significantly different between IL-6-/- mice ( • )  and IL-6+/+ mice (O) 
after injection of 0.25 mg, 0.5 mg, 1 mg, or 2 mg of LPS. Pooled data from 2-5 experiments were 
analyzed (10-29 mice per group).
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Outgrowth of K. pneumoniae in organs and blood
To assess whether the increased mortality of the IL-6-/- mice in the lethal K. 
pneumoniae infection model was associated with a higher bacterial load in the 
organs, groups of IL-6-/- and IL-6+/+ mice were sacrificed 24 hours after i.v. injection 
with 102 CFU of K. pneumoniae. The outgrowth of microorganisms in all of the 
specific organs, including peripheral blood, was significantly higher in IL-6-/- mice 
than in IL-6+/+ mice (Figure 3).
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Figure 3. Outgrowth of K. pneumoniae in the organs of IL-6-/- mice and IL-6+/+ mice.
IL-6-/- mice (n=9, hatched bars) and IL-6+/+ mice (n=8, open bars) were infected i.v. with 10 CFU per 
mouse. Mice were sacrificed 24 hours later and the number of CFU of K. pneumoniae from the 
organs and the blood was assessed. Data represent median ± quartiles of log CFU per gram of tissue 
for the organs, and median ± quartiles of log CFU per ml for blood. *P<0.05, **P<0.01, Mann-Whitney 
U test.
8
7
3
Recruitment of polymorphonuclear neutrophils
To investigate the recruitment of neutrophils at the site of a Klebsiella 
infection, groups of IL-6-/- and IL-6+/+ mice were injected intraperitoneally with 107 
CFU/ml heat-killed K. pneumoniae, and exudate peritoneal neutrophils were 
harvested and counted before injection and 4, 8, and 24 hours later. IL-6-/- mice had 
a reduced influx of neutrophils compated with IL-6+/+ mice, most prominently at 8 h 
after injection of the microorgansms (P<0.05; Figure 4)
Plasma glucocorticoid and cytokine levels during K. pneumoniae infection
To investigate the role of IL-6 in the activation of the HPA axis and in the 
release of pro-inflammatory cytokines during an ongoing Gram-negative infection, 
trunk blood was collected from IL-6-/- and IL-6+/+ mice at 4, 8 and 24 hours after i.v. 
injection with saline or with 102 CFU of K. pneumoniae. After injection of saline,
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plasma corticosterone levels did not differ between the two mouse strains (Figure 
5A). After injection of bacteria into IL-6+/+ mice, corticosterone levels increased 
within 4 hours, with highest levels observed at 8 hours, and subsequently decreased. 
In IL-6-/- mice corticosterone levels were significantly lower, compared to IL-6+/+ 
mice, at 4 and 8 hours after the injection of 102 CFU of K. pneumoniae (P<0.05). No 
differences in corticosterone response between IL-6-/- and IL-6+/+ mice were found 
after 24 hours (Figure 5A). TNFa plasma levels in IL-6-/- and IL-6+/+ mice increased 
within 4 to 8 hours after the onset of the infection with K. pneumoniae (Figure 5B). 
IL-6-/- mice had higher TNFa levels than IL-6+/+ mice at 8 and 24 hours after 
injection of K. pneumoniae (P<0.05). Figure 5C shows that IL-1 a levels in both 
mouse strains increased only marginally after infection with K. pneumoniae.
0 8 12 16 20 24 hours
Figure 4.Recruitment of granulocytes to the site of infection.
IL-6-/- mice ( • )  and IL-6+/+ mice (O) were injected intraperitoneally with 107 cfu of heat-killed 
Klebsiella pneumoniae and the numbers of granulocytes were assessed in cytospin preparations. 
Data are given as mean ± SD of 4 mice per group. *P<0.05.
Discussion
The present study demonstrates that IL-6-/- mice are more susceptible than 
IL-6+/+ mice to a systemic Gram-negative infection with K. pneumoniae, and that 
this infection is associated with a reduced adrenal response in IL-6-/- mice. Previous 
studies using Gram-negative bacteria (E. coli) (8), and other microorganisms (L. 
monocytogenes, M. tuberculosis, C. albicans, S. pneumoniae) (7, 18, 27, 34, 35), 
also demonstrated the protective role of IL-6 during lethal infections. In our study, the 
increased mortality in IL-6-/- mice was accompanied with a 10- to 100- fold increased
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outgrowth of K. pneumoniae in all of the organs analyzed. This difference between 
IL-6-/- and IL-6+/+ mice was already found at 24 hours after the i.v. injection of the 
microorganisms. The outgrowth of microorganisms in the first 1 to 3 days seems to 
determine the outcome of the survival of IL-6-/- and IL-6+/+ mice after 14 days, in 
three different infection models that were studied in our group: K. pneumoniae 
(present study), C. albicans (35), and Y. enterocolitica (JHAJ Curfs, FHJ van 
Enckevort, JFGM Meis, CGJ Sweep, ARMM Hermus, JAA Hoogkamp-Korstanje, 
Yersinia enterocolitica infection in IL-6-deficient mice. Abstract 13th British 
Scandinavian Conference on Infectious Diseases, 1997). In general, the early host 
response during the first days of bacterial and fungal infection is mediated by 
neutrophils, and a defective response may be explained by either a reduced 
recruitment of neutrophils at the site of infection or an impaired phagocytosis and 
intracellulkar killing of the organism. In the present study, the IL-6-/- mice displayed a 
reduced capacity to recruit neutrophils to the site of a Klebsiella injection. This is in 
agreement with earlier observations, showing that the recruitment of neutrophils is 
dependent on IL-6 in models of C. albicans infection (35) or peritoneal infection with 
S. epidermidis (15).
The infection with K. pneumoniae was accompanied by higher levels of the 
pro-inflammatory cytokine TNFa in IL-6-/- mice than in IL-6+/+ mice, at 8 and 24 
hours of the infection. Firstly, this could be explained by the diminished adrenal 
response in the first 8 hours in IL-6-/- mice, resulting in a reduced glucocorticoid 
suppression of immune cell functions and production of cytokines. Secondly, in the 
absence of endogenous IL-6 in these mice, a putative direct inhibiting effect of IL-6 
on the release of TNFa and IL-1 a is absent (1, 29), leading to higher levels of 
cytokines during the course of the infection. Thirdly, during sepsis and endotoxic 
shock, macrophage migration inhibitory factor (MIF) is induced, which acts to 
override the glucocorticoid inhibition of the production of cytokines (TNFa, IL-1 a and 
IL-6) in macrophages and T-cells (3, 4, 5). As IL-6 is an inhibitor of the release of 
MIF, we suggest that in IL-6-/- mice MIF levels are higher, which also may account 
for a reduced inhibition of cytokines by endogenous glucocorticoids in IL-6-/- mice. 
Most importantly, the higher bacterial load in IL-6-/- mice found at 24 hours of the 
infection may account for inducing more TNFa and IL-1 a.
The role of IL-6 in the activation of the HPA axis during septic shock or 
bacterial sepsis is not fully understood. In a previous study we showed that IL-6 
deficiency in mice results in a reduced adrenal response after injection with a single 
dose of purified LPS, although the plasma levels of TNFa and IL-1 a did not differ 
between IL-6-/- and IL-6+/+ mice in that model (36). Injection of a single dose of LPS 
resulted in a fast cytokine response with a peak of TNFa within 1 hour. The present 
results show a diminished corticosterone response until 8 hours after infection with 
K. pneumoniae, accompanied by higher TNFa levels in IL-6-/- mice. However, at 24 
hours of infection, corticosterone levels were equally high in IL-6-/- mice and in IL- 
6+/+ mice, where corticosterone levels had already started to decrease, while TNFa
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levels were still higher in IL-6-/- than in IL-6+/+ mice. On the basis of these results 
we suggest that IL-6 is important in the response of the HPA axis, and is a distinct 
mediator of the cytokine response to an infection with live microorganisms.
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Figure 5. Effect of i.v. injection with saline or with 102 CFU of Klebsiella pneumoniae 
on the plasma corticosterone (A), TNFa (B), and IL-1 a levels (C)
Data are given as mean ± SEM of 7-11 IL-6-/- ( • )  and IL-6+/+ (O) mice per group. *P<0.05 for 
difference between IL-6-/- and IL-6+/+ mice by one-way ANOVA, after establishing main effects on 
genotype and time in 2-way ANOVA.
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To assess whether the increased bacterial outgrowth per se, or the associated 
bacterial endotoxins induce the higher mortality of IL-6-/- mice during the infection 
with K. pneumoniae, purified LPS was injected into IL-6-/- and IL-6+/+ mice. In 
contrast to infection with K. pneumoniae, injection of mice with doses of 1 or 2 mg 
LPS shows no difference in mortality rates between IL-6-/- and IL-6+/+ mice, which is 
in accordance with the study by Dalrymple et al. (8). Moreover, in contrast to the 
higher levels of TNFa found in IL-6-/- mice during the infection reported here, no 
difference in TNFa levels was found between IL-6-/- and IL-6+/+ mice after injection 
of LPS (36). Therefore, the difference in mortality between the two mouse strains 
during the infection with K. pneumoniae is not mediated by LPS. Rather, the 
impaired neutrophil recruitment, leading to increased outgrowth of microorganisms in 
the absence of endogenous IL-6 is the main cause of the increased mortality in IL-6- 
/- mice.
We conclude that IL-6-/- mice are more susceptible to Gram-negative 
bacterial infections and to infections with live microorganisms in general, due to a 
defective migration of neutrophils to the site of infection and increased outgrowth of 
microorganisms in the organs of the mice. Furthermore, the reduced adrenal 
response may be an explanation for the strong inflammatory response with higher 
TNFa plasma levels in IL-6-/- mice.
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Abstract
Administration of bacterial lipopolysaccharide (LPS) in rodents induces the 
release of pro-inflammatory cytokines (TNF, IL-1, IL-6) and of ACTH and 
corticosterone. Interleukin-6 is probably an important cytokine in the interaction 
between the immune system and the hypothalamus-pituitary-adrenal (HPA) axis, but 
so far the role of IL-6 in LPS induced HPA activation has not been established 
unequivocally. We examined the effects of intraperitoneal administration of LPS 
(range 0.25 - 2000 g^/ mouse) on plasma corticosterone, TNFa and IL-1 a levels in 
IL-6-deficient (IL-6-/-) and wild-type control (IL-6+/+) mice. Plasma corticosterone 
levels increased within one hour in both mouse strains. The corticosterone response 
was significantly reduced in IL-6-/- mice, but no differences in TNFa or in IL-1 a 
plasma levels were found between the two strains. Next, we studied the involvement 
of IL-1 a or TNFa in the responses to LPS in IL-6-/- and IL-6+/+ mice by infusion of 
recombinant human IL-1 receptor antagonist (IL-1 ra), or by injection of anti-TNFa 
antibodies. Pretreatment with IL-1 ra or with anti-TNFa did not affect the 
corticosterone response to LPS, neither in IL-6-/-, nor in IL-6+/+ mice. Our data 
suggest that in the stimulation of the HPA axis by LPS in mice blockade of either IL- 
1a or TNFa may be compensated for by other mediators. The reduced adrenal 
response after LPS administration found in IL-6-/- mice indicates a distinct role for IL- 
6 in the activation of the HPA axis by LPS.
Introduction
During bacterial infections both the immune system and the hypothalamus- 
pituitary-adrenal (HPA) axis are activated (5, 18). There is ample evidence that 
during the acute phase of the inflammatory response lipopolysaccharide (LPS), a 
component of the cell wall of gram-negative bacteria, induces the release of pro- 
inflammatory cytokines like tumor necrosis factor (TNF), interleukin-1 (IL-1) and 
interleukin-6 (IL-6) by stimulation of mononuclear cells (14, 33, 43). Administration of 
LPS to rodents induces an increase in plasma levels of adrenocorticotropic hormone 
(ACTH) and corticosterone, characteristic for an activated HPA axis (7, 10, 31). 
Peripheral or central administrations of TNF, IL-1 and IL-6 have been found to 
increase ACTH and corticosterone release (2, 20, 25, 37, 41), and it is believed that 
the stimulation of the HPA axis during bacterial infections is mediated by pro- 
inflammatory cytokines (38). The concept has emerged that cytokines and 
glucocorticoid hormones integrate an immuno-regulatory feedback circuit: during 
stimulation of the immune system cytokines mediate an increase in plasma 
corticosterone levels. In turn, glucocorticoids will suppress immune cell functions and 
production of cytokines, thereby protecting the organism against a harmful overshoot 
of immune reactions (2, 6, 12, 16, 39).
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IL-6 reportedly plays an important role in the interaction between the immune 
system and the HPA axis (27). This pleiotropic cytokine is produced both by immune 
cells and by cells in endocrine tissues (24), including the hypothalamus (34, 35) and 
the pituitary gland (36). Furthermore, IL-6 has an inhibitory effect on the secretion of 
TNF and IL-1 (1, 33), and a direct stimulatory effect on glucocorticoid release by the 
adrenal (28, 32).
It has been shown that intraperitoneal (i.p.) injection of antibodies neutralizing 
IL-6 in normal mice inhibits the LPS induced increase in plasma ACTH levels (29). 
However, this study does not definitively prove that IL-6 is indeed an important 
mediator of the LPS induced stimulation of the HPA axis. More evidence for such a 
role of IL-6 could be obtained by investigating mice that are genetically deficient in 
the production of IL-6 (21). The effect upon the HPA axis can be studied by following 
the corticosterone concentration in plasma of IL-6-deficient (IL-6-/-) and wild-type 
control (IL-6+/+) mice. So far, there are only a few observations on corticosterone 
responses to LPS injection in IL-6-/- mice compared to those in IL-6+/+ mice (3, 12, 
22). The conclusion from preliminary observations, that IL-6 is not an important 
mediator in the LPS induced activation of the HPA axis, should be interpreted with 
caution as in both studies the corticosterone response to only one dose of LPS and 
at only one time point was analyzed (12, 22). In the more recent study by Bethin et 
al. (3) a later time point was chosen for the evaluation of plasma levels after injection 
of LPS, thus revealing that corticosterone levels in IL-6-/- mice were lower than in IL- 
6+/+ mice.
In the present study we examined the effects of i.p. administration of different 
doses of LPS (range 0.25 - 2000 ^g) to IL-6-/- and IL-6+/+ mice on the plasma levels 
of corticosterone, as well as on the plasma levels of the pro-inflammatory cytokines 
TNFa and IL-1 a, between 0 and 8 hours after injection of LPS. To study the possible 
involvement of IL-1 a in the stimulation of the corticosterone release in IL-6-/- and IL- 
6+/+ mice, an IL-1 receptor antagonist was administered via continuous infusion with 
osmotic pumps, followed by an i.p. injection of LPS. In addition, we investigated the 
role of TNFa in the LPS induced corticosterone response in these mice by 
intravenous (i.v.) injection of anti-TNFa neutralizing antibodies prior to LPS 
administration.
Materials and Methods 
Animals
Breeding pairs from the mixed (C57Bl/6 x 129/Sv) F2 generation of both IL-6- 
deficient (IL-6-/-) and wild-type control (IL-6+/+) mice were obtained from the Max- 
Planck-Institut für Immunbiologie, Freiburg, Germany (21). In the IL-6-/- mice, the IL- 
6 gene is disrupted in the second exon by homologous recombination. Homozygous 
IL-6-/- and IL-6+/+ mice were housed under specific pathogen free conditions
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[according to FELASA recommendations (30)] at the Central Animal Laboratory of 
the University of Nijmegen. Standard safety and breeding protocols for transgenic 
mice were followed.
Male offspring of 10-16 weeks old, weighing 20-30 grams, all healthy, were 
used. Mice were housed individually from two days before until the end of each 
experiment. Mice were kept under a 12/12 hours dark/light cycle (lights on at 07:00 
h) and received acidified water and standard food (Hope Farms, Woerden, The 
Netherlands) ad libitum.
Verification of IL-6-deficiency
Mice in the breeding facilities were confirmed to be homozygous IL-6-/- or IL- 
6+/+ by Polymerase Chain Reaction (PCR) analysis. Genomic DNA was isolated 
from toe clip tissue using the Puregene DNA isolation kit D-5000A (Biozym, 
Landgraaf, The Netherlands) according to the manufacturer’s protocol. PCR was 
performed using basic protocols (19) with three primers for 34 cycles at 92 °C x 30 
sec, 55 °C  x 30 sec, 72 °C  x 90 sec. The IL-6 primers 5'-TTC-CAT-CCA-GTT-GCC- 
TTC-TTG-G-3', 5'-TTC-TCA-TTT-CCA-CGA-TTT-CCC-AG-3', and the Neo primer 5'- 
CCG-GAG-AAC-CTG-CGT-GCA-ATC-C-3' were purchased from Eurogentec 
(Eurogentec, Seraing, Belgium). PCR products were visualized on horizontal 
agarose gels with Ethidium Bromide under UV light in order to determine the correct 
genotype. Only offspring from homozygous mice were used in the experiments.
Materials
Lyophilized lipopolysaccharide (LPS) serotype 0111:B4 from E.coli was 
purchased from Sigma (Sigma, St. Louis, MO). LPS was dissolved in sterile 
physiological saline (0.9% NaCl) and was immediately diluted to the appropriate 
concentrations in LPS free polypropylene sample tubes. Dilutions were kept at -20 
°C and were brought to room temperature before injection. Recombinant human 
interleukin-1 p (rhIL-1 p, Glaxo IMB, Geneva, Switzerland) was stored at -80 °C and 
was diluted just before use. The rhIL-1p (batch RNB 18511/14-B) had a specific 
activity of 2.5x107 U/mg protein in the LAF assay and endotoxin contamination was 
negligible. Recombinant human IL-1 receptor antagonist (IL-1ra) was kindly provided 
by Dr. R.C. Thompson (Synergen, Boulder, CO). Concentrated solutions of 100 mg 
IL-1ra/ml physiological saline were kept at -80 °C  and were diluted just before use. 
Neutralizing rat anti-murine TNFa monoclonal antibodies (MoAbs) produced by V1Q 
hybridoma cells (kindly provided by Dr. P.H. Krammer, Heidelberg, FRG) were used 
as described before (17). The amount of anti-TNFa MoAbs neutralizing 1 unit of 
recombinant murine TNFa was defined as one neutralizing unit (nU). Rat IgG from 
Sigma (Sigma, St. Louis, MO) was used as control. All other chemicals used were of 
analytical grade.
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Experimental protocols
A completely randomized setup for pretreatment, genotype, treatment, and 
time of blood sampling was used in all experiments with IL-6-/- and IL-6+/+ mice. 
Experiments were repeated until 6-9 mice were pooled in each group.
Effects of LPS administration on plasma corticosterone and cytokine levels
LPS was injected i.p. (200 Ml) at 09:00 h in a dose of 0.25, 2.50, 25.0 or 2000 
Mg per IL-6-/- or IL-6+/+ mouse. Injections with sterile physiological saline were used 
as controls. At 1, 2%, 4 and 8 hours after injection different groups of animals were 
decapitated to obtain trunk blood (7-9 mice per group).
Effect of IL-1 ra pretreatment on the rhIL-1 P and LPS induced responses of plasma 
corticosterone and cytokine levels
Alzet micro-osmotic pumps model 1003D (100 Ml, 3 days, release 1 |jl/h, Alza, 
Palo Alto, CA) were filled with a solution of 2 mg recombinant human IL-1 ra/100 Ml 
saline, or with sterile physiological saline, according to the supplier’s instructions. 
Alzet pumps were implanted into the peritoneal cavity of IL-6-/- and IL-6+/+ mice 
under mild ether anaesthesia. Mice recovered well within a few hours and were 
housed individually to prevent wound biting. To monitor recombinant human IL-1 ra 
levels in the plasma of a mouse following osmotic pump implantation, blood was 
collected by orbita punction (40 Ml) at the time of operation and 2, 4, 6, 24, 48 and 72 
hours later. Two days after implantation of the pumps IL-6-/- mice were injected i.p. 
with rhIL-1 p (80 ng) to check whether the infused IL-1 ra is able to block the 
corticosterone response to rhIL-1 p. One hour after rhIL-1 p injection, trunk blood was 
obtained by decapitation (4-5 mice per group). In subsequent experiments IL-6-/- 
and IL-6+/+ mice were injected i.p. at 09:00 h with saline or with 0.25 or 2000 Mg 
LPS, two days after implantation of the pumps. One, 2% and 4 hours after injection, 
blood samples were obtained by decapitation (6 mice per group).
Effect of anti-TNFa pretreatment on the LPS induced response of plasma 
corticosterone levels
IL-6-/- and IL-6+/+ mice were given anti-TNFa neutralizing antibodies (50,000 
nU in 100 Ml), as described by Hermsen et al. (17), or control IgG (50 Mg in 100 Ml) in 
the orbital plexus under mild ether anaesthesia at 09:00 h. Four hours later mice 
were injected i.p. with saline or 0.25 Mg LPS, and 2% hours thereafter blood samples 
were obtained by decapitation (6 mice per group). We have demonstrated earlier 
(34) that administration of this dose of 50,000 neutralizing units of anti-TNFa 
monoclonal antibodies before injection of 100 Mg LPS significantly reduced 
immunoreactive TNFa concentrations and reduced bioactive TNFa concentrations to 
below the detection limit.
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Figure 1 (on opposite page). Effect of i.p. injection of saline or different doses of 
lipopolysaccharide (LPS) at t=0 on the plasma corticosterone levels (A, left panel) and 
plasma TNFa levels (B, right panel) in IL-6-deficient (IL-6-/-, • )  and wild-type control 
(IL-6+/+, O) mice.
A: Significant main effects and interactions by genotype, time, and dose of LPS resulted from the 3­
Way ANOVA (p<0.05). Significant genotype by time (GxT) interactions are indicated in the graph of 
each dose (2-Way ANOVA). At all doses of LPS the overall plasma corticosterone response was 
significantly lower in IL-6-/- than in IL-6+/+ mice. An asterisk (*) indicates significant difference 
between the two genotypes at the specific time point in each graph (one-way, p<0.05). At the low 
dose of 0.25 Mg LPS significantly higher corticosterone levels were found in the IL-6+/+ mice at 2% 
and 4 h after injection.
B: Only significant main effects and interactions by time, and dose of LPS resulted from the 3-Way 
ANOVA (p<0.05). No significant main effect by genotype was found, so no further comparison of 
group means was performed. Thus, no significant differences in TNFa response were found between 
IL-6-/- and IL-6+/+ mice.
Data represent mean + SE of 7-9 mice per group.
Blood Sample Analyses
Blood was collected on ice in (K3 ) EDTA Monoject Samplette whole blood 
collector tubes (Sherwood Medical, St.Louis, MO) to which 250 KIE aprotinine (25 Ml, 
Trasylol, Bayer AG, Leverkusen, Germany) was added. Collected blood was 
centrifuged for 10 minutes at 1,500x g (4 °C), and plasma was separated and stored 
at -20 °C  until assay. Corticosterone levels were determined by radioimmunoassay 
(RIA) after extraction by dichloromethane as described before (37). TNFa and IL-1 a 
antigen values were measured by in-house RIAs for mouse TNFa and IL-1 a (26), 
and recombinant human IL-1 ra was assayed by an in-house human IL-1 ra RIA (9). 
Detection limits of the cytokine assays were 0.04, 0.02 and 0.6 ng/ml, respectively.
Statistical Analysis
A 3-Way analysis of variance (3-Way ANOVA) model was used to investigate 
the main effects (genotype, time, treatment) and the interactions for each blood 
sample variable (corticosterone, TNFa, IL-1 a). For experiments that included 
pretreatment with IL-1 ra or anti-TNFa a 4-Way ANOVA model with a fourth main 
effect (pretreatment) was used. Where main effects or interactions were found, 
further comparisons of group means by 2-Way and One-way ANOVA were carried 
out when appropriate, using Bonferroni corrections to maintain the overall level of 
significance at p<0.05. Student’s t test was used for analysis of the effect of rhIL-1 p 
injection after pretreatment with IL-1 ra. Statistical analysis package SP S S  version 
6.1.3 (SP SS  Benelux bv, Gorinchem, The Netherlands) was used.
Results 
Effects of LPS administration on plasma corticosterone and cytokine levels
Figure 1A shows the effect of i.p. injections of saline and of 0.25, 2.50, 25.0 
and 2000 Mg LPS on plasma corticosterone levels in IL-6 -/- and IL-6 +/+ mice.
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Plasma corticosterone levels were increased above values obtained by saline 
injection within one hour after LPS injection both in IL-6-/- and in IL-6+/+ mice. At all 
doses of LPS the overall plasma corticosterone response was significantly lower in 
IL-6-/- than in IL-6+/+ mice (p<0.05). At the low dose of 0.25 Mg LPS significantly 
higher corticosterone levels were found in the IL-6+/+ mice at 2% and 4 hours after 
injection (p<0.05). In both strains corticosterone values returned to basal levels 
within 8 hours after injection. After injection of 2.50 Mg LPS maximum plasma 
corticosterone levels were reached after 2%-4 hours; thereafter the values slightly 
declined, but they were still elevated at 8 hours after injection. At the doses of 25.0 
and 2000 Mg LPS corticosterone plateau levels were reached within 1-2% hours 
which lasted up to 8 hours after injection.
Figure 1B shows that i.p. injections of different doses of LPS in both mouse 
groups induced a transient increase in plasma levels of TNFa, whereas no effect of 
saline injection was observed. For all doses, the TNFa peak value was reached at 1 
hour following injection of LPS both in IL-6-/- and in IL-6+/+ mice. The highest peak 
level was found after injection of 25.0 Mg LPS in both strains. After 2000 Mg LPS the 
plasma TNFa levels did not reach this maximum, but the levels declined slower and 
remained slightly elevated at 4 and 8 hours after injection. No significant differences 
in TNFa response were found between IL-6-/- and IL-6+/+ mouse groups.
After i.p. injection of 0.25, 2.50, or 25.0 Mg LPS plasma levels of IL-1 a were 
not different from values in saline treated control animals (values between 0.1 and
0.2 ng/ml in all groups). After injection of the highest dose of LPS (2000 Mg), plasma 
IL-1 a levels gradually increased and reached values of 1 ng/ml at 8 hours both in IL- 
6-/- and in IL-6+/+ mice. No significant difference in IL-1 a response was observed 
between the two genotypes (data not shown).
Effect of IL-1ra pretreatment on the rhlL-1fi and LPS induced responses of 
plasma corticosterone and cytokine levels
To confirm that high circulating levels of IL-1 ra were maintained for 2 days 
following osmotic pump implantation, an Alzet micro-osmotic pump releasing 20 Mg 
recombinant human IL-1 ra per hour was implanted into the peritoneal cavity of one 
mouse, and the IL-1 ra values in blood were assessed. Recombinant human IL-1 ra 
values in orbital blood samples obtained at the time of operation of the mouse and 2 
hours later were below the detection limit of the assay (< 0.6 ng/ml), while at 4, 6, 24, 
48 and 72 hours following the implantation plasma IL-1 ra values of 270, 1150, 690, 
730 and 195 ng/ml, respectively, were measured. Therefore, 48 hours after 
implantation of the pumps was chosen as the time point of injection of recombinant 
human IL-1 p (rhIL-1 p) or LPS in all further experiments, and circulating IL-1 ra levels 
at that time were confirmed to be 793 ± 386 ng/ml (mean ± SD, n=113, range 45­
2000 ng/ml). Plasma IL-1 ra levels in mice that were implanted with control pumps 
releasing saline were all around the detection limit of the assay (0.6 ng/ml).
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Figure 2. Effect of 2 days pretreatment via osmotic pumps with IL-1ra (■, □ ) or saline 
( • ,  O) on the plasma corticosterone levels (A, left panel), the plasma TNFa levels (B, 
middle panel), and the plasma IL-1a levels (C, right panel) after i.p. injection of saline 
or different doses of LPS at t=0 in IL-6-/- (■, • )  and IL-6+/+ (□ , O) mice.
A: Significant main effects and 3-Way interactions by genotype, time, and dose of LPS resulted from 
the 4-Way ANOVA (p<0.05). Significant genotype by time (GxT) interactions are indicated in the 
graph of each dose (2-Way ANOVA). An asterisk (*) indicates significant difference between the two 
genotypes at the specific time point in each graph (one-way, p<0.05). No significant main effect or 
interactions by pretreatment (RA) were found.
B: Only significant main effects and interactions by time, and dose of LPS resulted from the 4-Way 
and subsequent 2-Way ANOVA’s (p<0.05). No significant main effect by either pretreatment or 
genotype and no 4-Way or 3-Way interactions were found.
C: Significant main effects by pretreatment, genotype, time, and dose of LPS were found in the 4-Way 
ANOVA (p<0.05). Significant genotype by time (GxT) interactions and pretreatment by time (RAxT) 
interactions are indicated in the graph of each dose when relevant (2-Way ANOVA’s). An asterisk (*) 
indicates significant difference between the two genotypes at the specific time point in each graph 
(one-way, p<0.05). One hash (#) indicates difference between the two pretreatment groups of IL-6-/- 
mice, and a double hash (##) indicates difference by pretreatment of IL-6+/+ mice at the specific time 
points (One-way, p<0.05).
Data represent mean + SE of 6 mice per group.
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With this experimental protocol it was assessed whether the high circulating 
levels of recombinant human IL-1 ra, reached by infusion of this peptide, were indeed 
effective in antagonizing the rhIL-1 p induced effects on corticosterone release in the 
mouse. Basal plasma corticosterone levels in IL-6-/- mice were 97 ± 40 nmol/l (mean 
± SEM, n=9). One hour after i.p. injection of 80 ng rhIL-1 p in IL-6-/- mice with control 
pumps the plasma corticosterone levels were 580 ± 140 nmol/l (mean ± SEM, n=5), 
while the corticosterone response at 1 hour after rhIL-1 p injection in IL-1 ra infused 
IL-6-/- mice was significantly blocked to levels of 119 ± 43 nmol/l (mean ± SEM, n=4, 
p<0.05).
Figure 2A shows the effect of i.p. administration of saline and of 0.25 and 
2000 ^g LPS on plasma corticosterone levels in IL-6-/- and IL-6+/+ mice which 
received continuous infusion with either IL-1 ra or saline via osmotic pumps for two 
days. Within one hour after injection of saline a small rise in plasma corticosterone 
levels was observed both in IL-6-/- and in IL-6+/+ mice, whereas corticosterone 
levels were clearly increased after LPS injection. Injection of the low dose of 0.25 Mg 
LPS induced a transient increase in plasma corticosterone levels, while at a high 
dose of 2000 Mg LPS corticosterone plateau levels were reached at 1-2% hours post 
injection. As in the experiments without pretreatment, the overall plasma 
corticosterone values were significantly lower in IL-6-/- than in IL-6+/+ mice (p<0.05). 
Pretreatment with IL-1 ra infusion did not significantly affect the corticosterone 
response to LPS in either of the mouse strains, compared to saline infusion.
Figure 2B shows that plasma TNFa levels were increased after i.p. injection of 
LPS in IL-6-/- and in IL-6+/+ mice which received either IL-1 ra or saline infusion. 
Saline injection had no effect on plasma TNFa levels. One hour after injection of 0.25 
Mg LPS a small peak was observed, while plasma TNFa levels declined to values 
around detection limit of the assay (0.04 ng/ml) at 2% hours after injection. After 
administration of 2000 Mg LPS a more prolonged elevation of TNFa levels was found 
in IL-6-/- as well as in IL-6+/+ mice. For both mouse strains, no significant difference 
in TNFa response to LPS was observed when IL-1 ra infused mice were compared to 
saline infused control mice.
Figure 2C shows plasma levels of IL-1 a after i.p. administration of saline, 0.25 
or 2000 Mg LPS to IL-1 ra or saline infused IL-6-/- and IL-6+/+ mice. After injection of
0.25 Mg LPS, the IL-1 a levels in all mouse groups were similar to the basal IL-1 a 
levels in the saline injected control groups. At 2% and 4 hours after injection of 2000 
Mg LPS the plasma IL-1 a levels in all groups were increased. At this dose of LPS, 
the pretreatment with IL-1 ra resulted in significantly higher IL-1 a levels than saline 
control pretreatment in both mouse strains (p<0.05, # and ## at 2% and 4 hours). IL- 
6-/- mice with IL-1 ra pretreatment had higher LPS induced IL-1 a levels than IL-6+/+ 
mice with IL-1 ra pretreatment (p<0.05, * at 2% hours).
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Effect of anti-TNFa pretreatment on the LPS induced response of plasma 
corticosterone levels
To investigate the involvement of TNFa in the LPS induced corticosterone 
response in IL-6-/- and IL-6+/+ mice, anti-TNFa monoclonal antibodies (50,000 nU in 
100 Ml) or control IgG solution (50 Mg in 100 Ml) was administered intravenously to 
mice of both strains 4 hours before injection of saline or LPS. Table 1 shows that 
plasma corticosterone levels were significantly lower for IL-6-/- compared to those for 
IL-6+/+ mice at 2% hours after i.p. injection of 0.25 Mg LPS (p<0.05). Pretreatment 
with anti-TNFa induced no significant difference in corticosterone response 
compared to control IgG injection either in IL-6-/- or in IL-6+/+ mice.
Table 1. Effect of pretreatment with anti-TNFa on the LPS induced corticosterone 
response in IL-6-/- and IL-6+/+ mice.
Genotype Pretreatment Saline LPS 0.25 Mg
IL-6-/- IgG control 262 ± 36 498 ± 83 *
anti-TNFa 240 ± 25 362 ± 36 *
IL-6+/+ IgG control 284 ± 24 991 ± 103
anti-TNFa 250 ± 23 1018 ± 46
IL-6-/- and IL-6+/+ mice were pretreated (4 h before LPS) with IgG (50 Mg in 100 Ml) or anti-TNFa 
(50,000 nU in 100 Ml), and the effects of i.p. administration of saline or 0.25 Mg of LPS on plasma 
corticosterone levels (2% h later) were examined. Data are presented as mean corticosterone levels 
(nmol/l) ± SEM of 6 mice per group.
* p<0.05 IL-6-/- vs. IL-6+/+.
Discussion
There is ample evidence that the pro-inflammatory cytokines TNF, IL-1 and IL-6 are 
involved in the stimulation of the HPA axis after injection of LPS in rodents (39). 
Despite many studies, however, the individual roles of these three cytokines in the 
LPS induced response of the HPA axis are not clear. Here, we demonstrate that the 
LPS induced elevation of plasma corticosterone levels is significantly reduced in IL- 
6-deficient mice compared to wild-type control mice, whereas blockade of either 
IL-1 a or TNFa did not affect the stimulation of the HPA axis by LPS, neither in IL-6-/- 
nor in IL-6+/+ mice. Our data suggest that in the stimulation of the HPA axis by LPS 
in mice blockade of either IL-1 a or TNFa may be compensated for by other 
mediators. The reduced adrenal response after LPS administration found in IL-6-/- 
mice indicates a distinct role for IL-6 in the activation of the HPA axis by LPS.
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Our results concur with an earlier study in which administration of anti-IL-6 
antibodies blocked the ACTH response in mice at 2 and 4 hours after challenge with 
LPS in doses of 1 and 5 Mg, respectively (29), and with another study, in which 
administration of anti-IL-6 antibodies blocked the ACTH and the corticosterone 
response in mice at 3 hours, but not at 1 hour, after administration of LPS in a dose 
of 2 Mg (42). In addition, similar results were obtained in a study by Bethin et al. 
using IL-6-/- mice, which were injected with a dose of 300 ^g LPS. Corticosterone 
levels were lower in IL-6-/- mice when measured 3 hours after injection of LPS (3).
Our results seem to be at variance with those of two other studies which 
reported that the response of plasma corticosterone after LPS injection is not 
different between IL-6-/- and IL-6+/+ mice (13, 22). In these studies, however, 
plasma corticosterone levels were measured only once, at 1% hours after 
intraperitoneal injection of LPS in doses of 1 or 2.5 mg/kg body weight 
(approximately 25 to 75 Mg/mouse). It has to be noted that at this particular time 
point after injection of a similar dose of LPS also in our study an equal corticosterone 
response was found in IL-6-/- and IL-6+/+ mice. Especially at later time points (2%, 4 
and 8 hours), and notably to all of the doses of LPS tested in our study, the 
difference in corticosterone response between IL-6-/- and IL-6+/+ mice was 
apparent.
Similar observations on the activation of the HPA axis in IL-6-/- versus IL-6+/+ 
mice were made after induction of local inflammation by subcutaneous injection with 
turpentine. Also here a clear time effect was observed. Plasma corticosterone levels 
at 1% hours after turpentine injection in IL-6-/- and IL-6+/+ mice were similar (13, 
22), whereas a markedly blunted corticosterone response was observed in IL-6-/- 
mice at 9 hours after turpentine injection, a time point more corresponding to the 
HPA axis response to the actual inflammatory stimulus (39). In our study the 
differences in corticosterone levels between IL-6 -/- and IL-6 +/+ mice were most 
prominent at low doses of LPS. Apparently, with the highest dose of LPS a maximal 
stress response is induced, in both mouse strains, in which the contribution of 
endogenous IL-6 is less essential. These findings from previous studies, as well as 
the results from the present study, illustrate the need for studies using multiple doses 
and multiple time points to elucidate the role of IL-6 in the inflammation-induced HPA 
axis activation.
The stimulatory effect of LPS on the HPA axis reportedly comprises an 
increased IL-1 concentration (38, 43). To elucidate whether IL-1 a actually plays a 
crucial role in the stimulating effect of LPS on plasma corticosterone levels, we 
investigated whether blocking the IL-1 receptor by pretreatment with recombinant 
human IL-1 receptor antagonist influenced the corticosterone response to LPS 
injection in normal IL-6+/+ mice, as well as in IL-6-/- mice. Recombinant human IL-1 
receptor antagonist administration has been demonstrated to block IL-1 type I 
receptors in rodents (8). As the blood clearance of recombinant human IL-1 ra in 
mice is very rapid (40), we administered IL-1 ra intraperitoneally by continuous
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infusion in IL-6-/- as well as in IL-6+/+ mice, using Alzet micro-osmotic pumps. In our 
study, pretreatment with recombinant human IL-1 ra was associated with high 
circulating levels of recombinant human IL-1 ra in mice up to a 1000-fold molar 
excess over endogenous mouse IL-1 a, which reportedly is required for inhibition of 
the IL-1 receptor (8). This indeed appeared to result in an effective blocking of 
increasing corticosterone levels after an i.p. challenge with recombinant human IL- 
1P, an agonist for the IL-1 type I receptor in the mouse. Nevertheless, pretreatment 
with recombinant human IL-1 ra did not influence the LPS induced corticosterone 
response, neither in IL-6-/-, nor in IL-6+/+ mice. Our results indicate that IL-1 a is not 
as important as IL-6 as a mediator of the LPS induced corticosterone response. Our 
data agree with those of Dunn (11), who showed that plasma ACTH and 
corticosterone responses at 2, 4, and 6 hours after i.p. administration of 1 ^g LPS 
were not altered when mice were pretreated with an i.p. injection of 1 mg 
recombinant human IL-1 ra. Although administration of IL-1 activates the HPA axis, 
these data suggest that IL-1 is not critically involved in the response of the HPA axis 
to intraperitoneal LPS administration.
In our study, pretreatment with IL-1 ra induced an augmentation of plasma IL- 
1a concentrations after LPS injection in both IL-6+/+ and IL-6-/- mice, as compared 
to pretreatment with saline. This indicates a negative feedback mechanism to be 
involved in the production and/or release of IL-1 a. Furthermore, as IL-6-/- mice 
showed higher IL-1 a plasma levels than IL-6+/+ mice after the injection of the 
highest dose of LPS in combination with IL-1 ra, IL-6 seems to be a mediator in this 
feedback mechanism.
Our study does not provide evidence that TNFa plays a major role in the 
stimulation of the HPA axis by LPS. When anti-TNFa antibodies were administered 
prior to the injection of LPS, in a dose that effectively reduces immunoreactive and 
bioactive TNFa concentrations after an i.p. injection of 100 ^g of LPS (17), neither in 
IL-6+/+, nor in IL-6-/- mice a significant reduction of the response of plasma 
corticosterone was found at 2% hours after LPS injection. Our results concur with the 
studies of Dunn (10). However, Hadid et al. (15) showed that pretreatment of mice 
with anti-TNFa caused an attenuated ACTH and corticosterone response at 6 hours, 
but not at 2 hours, after i.p. injection of LPS.
IL-6 reportedly inhibits LPS induced TNF release in vitro (1). Therefore we 
expected that the LPS induced TNFa response would be greater in IL-6-/- than in IL- 
6+/+ mice which, however, was not found in the present study. Apparently, IL-6 
deficiency has no significant effect in vivo on the fast, but short lasting stimulation of 
TNFa secretion after administration of LPS.
In our study, the TNFa and IL-1 a responses to LPS were essentially normal in 
IL-6-/- mice, suggesting that IL-6 is not involved in the LPS induced increase in TNFa 
and IL-1 a. In spite of these normal TNFa and IL-1 a levels, the adrenal response to 
LPS was attenuated in these mice. These results suggest that IL-6 is involved in the 
TNFa and IL-1 a induced activation of the HPA axis after i.p. LPS injection. This
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concurs with the results of Chai et al. (4), who showed that IL-6 probably acts 
downstream of IL-1 p in inducing a fever response to LPS, and with results from 
Libert et al. (23) who showed that IL-6-/- mice exhibit a lower corticosterone 
response to TNFa than IL-6+/+ mice. Temporal and causal relationships have been 
suggested between the elevated plasma concentrations of TNF, IL-1, and IL-6, in 
this order, after the injection of LPS (39).
Remarkably, at 1 hour after injection of LPS, the corticosterone response is 
normal in IL-6-/- mice in our study as well as in other studies (13, 22). This indicates 
that in the early activation of the HPA axis IL-6 is not essential for a competent 
adrenal response to LPS. However, 2% and 4 hours after LPS injection, IL-6-/- mice 
are not able to exhibit a full adrenal response. Thus, other cytokines cannot fully 
compensate for a lack of IL-6 in this later phase of the LPS induced activation of the 
HPA axis. As blockade of the TNFa or IL-1 a response has no effect on the adrenal 
response to LPS, it seems that these cytokines, probably due to a redundancy of 
pro-inflammatory cytokines and alternative pathways, are less crucial than IL-6 in the 
LPS induced activation of the HPA axis.
In summary, impaired IL-6 production reduces the adrenal response to LPS, 
whereas (additional) blockade of either IL-1 a or TNFa does not (further) reduce the 
adrenal response to LPS. Our results suggest that in the activation of the 
hypothalamic-pituitary-adrenal axis by LPS in mice, blockade of either IL-1 a or TNFa 
may be compensated for by other mediators, and our results demonstrate that IL-6 
plays a distinct role in the stimulation of the HPA axis by LPS.
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Abstract
Although hypothalamic corticotropin-releasing hormone (CRH) is involved in 
the stress response in all vertebrate groups, only a limited number of studies on this 
neuroendocrine peptide deals with nonmammalian neuroendocrine systems. We 
determined the cDNA sequence of the CRH precursor of the teleost Oreochromis 
mossambicus (tilapia) and studied the biological potency of the CRH peptide in a 
homologous teleost bioassay. Polymerase Chain Reaction (PCR) with degenerate 
and specific primers yielded fragments of tilapia CRH cDNA. Full-length CRH cDNA 
(988 nucleotides) was obtained by screening a tilapia hypothalamus cDNA library 
with the tilapia CRH PCR products. The precursor sequence (167 amino acids) 
contains a signal peptide, the CRH peptide and a motif conserved among all 
vertebrate CRH precursors. Tilapia CRH (41 aa) displays between 63% and 80% 
amino acid sequence identity to CRH from other vertebrates, whereas the degree of 
identity to members of the urotensin I/ urocortin lineage is considerably lower. In a 
phylogenetic tree, based on alignment of all full CRH peptide precursors presently 
known, the three teleost CRH precursors (tilapia; sockeye salmon, Oncorhynchus 
nerka; white sucker, Catostomus commersoni) form a monophyletic group distinct 
from amphibian and mammalian precursors. Despite the differences between the 
primary structures of tilapia and rat CRH, maximally effective concentrations of 
tilapia and rat CRH were equally potent in stimulating ACTH and a-MSH release by 
tilapia pituitaries in vitro. The tilapia and salmon CRH sequences show that more 
variation exists between orthologous vertebrate CRH structures, and teleost CRHs in 
particular than previously recognized. Whether the structural differences reflect 
different mechanisms of action of this peptide in the stress response remains to be 
investigated.
Introduction
In all vertebrate groups, hypothalamic corticotropin-releasing hormone (CRH) 
achieves its integrative role in the stress response (11) through two mechanisms of 
action. Firstly, this member of the corticotropin-releasing factor (CRF) family of 
peptides exerts stimulatory control over the pituitary-adrenal axis via stimulation of 
adrenocorticotropic hormone (ACTH) release in particular, and probably also via 
stimulation of a-melanocyte stimulating hormone (a-MSH) release (7, 43). The 
resulting rapid elevation of circulating glucocorticoids is life sustaining for the animal, 
for instance following immune activation, when CRH plays a crucial role in immune- 
endocrine interactions. Pro-inflammatory interleukin-1 (IL-1) stimulates CRH 
secretion, which restrains the activated immune system through elevated 
glucocorticoid secretion (11). In Lewis rats, which display a high susceptibility to 
bacterial cell wall induced arthritis, this IL-1 regulated CRH activation is defective
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which, compared to a reference rat strain, results in a lower response of the pituitary- 
adrenal axis to IL-1 (41). Secondly, several other processes are directly regulated by 
CRH, independent of pituitary-adrenal activation. Involvement of CRH has been 
reported for regulation of the reproductive system (35), of body temperature, food 
intake, growth and thyroid functions (12, 30). These regulations are achieved 
predominantly via neuromodulatory and paracrine mechanisms. For instance, CRH 
inhibits hypothalamic gonadotropin releasing hormone (GnRH) cells in vivo (15) and 
in vitro (44), and in fish CRH stimulates thyrotropin secretion from the pituitary in 
vitro (25).
The conclusion (26, 27) that the 41 amino acid CRH peptide has been 
strongly conserved would appear consistent with the strong conservation of the 
stress response, which becomes evident from the similarities between the 
physiological actions of the primary stress hormones from fish to mammals. The 
lowest degree of identity (76%) is found between human CRH (39) and sockeye 
salmon CRH (2) peptides, but the identity between human CRH peptide and that of 
the teleost white sucker (29) is very high (95%). This points to marked species 
differences among the teleosts and, as teleost fishes represent the vertebrate group 
with the highest number of extant species (over 20.000), neither of the two fish CRH 
peptides might be suitable for physiological studies in other teleosts.
The role of CRH in the teleost endocrine stress response may be species 
specific. Previously we showed for tilapia, an advanced teleost, that following an 
appropriate stimulus, the elevation of plasma cortisol levels occurs extremely rapidly
(6). This cortisol surge may even precede the rise in ACTH, which contrasts with the 
situation in salmonids (33, 43). A very slow increase in plasma cortisol levels is 
found in sea raven, a teleost with a sluggish life-style (49). Because these 
differences might partly originate at the level of the hypothalamus, the first aim of the 
present study is to determine the precursor cDNA sequence of tilapia CRH.
As knowledge of the function of CRH in teleosts is incomplete, the second aim 
of the present work is to test the biological potency of the synthesized tilapia CRH in 
a homologous teleost bioassay and to compare its ACTH and a-MSH releasing 
activity with that of rat CRH. Such data have not been published for fish CRH. Data 
concerning bioactivity for the recently sequenced sockeye salmon CRH (2) are not 
available, although the various differences in amino acids with mammalian CRH 
suggest differences in bioactivity (9, 24). Synthetic white sucker CRH is reported to 
have similar ACTH releasing potency with that of rat, human and ovine CRH, but this 
was tested on goldfish pituitary (26).
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Materials and Methods
Isolation of tilapia CRH cDNA by Polymerase Chain Reaction
Genomic DNA was isolated from the livers of male and female tilapia following 
standard procedures (37). TRIzol Reagent (Gibco BRL), based on the guanidinium 
isothiocyanate-phenol-chloroform method (10), was used for the isolation of total 
RNA from tilapia hypothalami. First strand cDNA was prepared by use of Superscript 
reverse transcriptase (RT) and an oligo(dT)17 primer 5' CCG AAT TCG GAT CCT 
CTA GTT TTT TTT TTT TTT TTT 3' at 45°C for 60 minutes. Polymerase Chain 
Reactions (PCR) on genomic DNA and on cDNA were performed using adapted 
protocols (22) for 40 cycles at 94°C x 60", 50°C x 90", 70°C x 60" with several sets of 
primers. Reagents for RT and PCR were from Boehringer Mannheim (Germany) and 
from Gibco-BRL (USA). Degenerate primer sets were based on the known CRH 
sequences of human (39), sheep (17), rat (23), clawed toad (40), and the teleost 
sequence identified previously from white sucker (29). Degenerate primers 
(Eurogentec, Seraing, Belgium) were based on conserved regions of CRH: primer 
crh5sense 5' GG GGG ATC CT(AGCT) (AC)G(AGCT) GA(AG) GTI (CT)TI GA(AG) 
ATG 3', primer crh6anti 5' CC CGA ATT CC(GT) (AG)TT (AG)CT (AG)TG 
(AGCT)GC (CT)TG (CT)T 3', primer crh7sense 5' GG CTC TAG AT(AGCT) 
TC(AGCT) (ATC)TI GA(CT) (CT)TI ACI TT(CT) CA 3'. Inosine (I) was used to limit 
the degeneracy. For PCR on hypothalamic cDNA also the adapter primer 5' CCG 
AAT TCG GAT CCT CTA GTT 3' was combined with crh5sense and crh7sense. 
Primers contained recognition sites for cloning purposes: EcoRI and BamHI in the 
adapter primer, BamHI in crh5sense, EcoRI in crh6anti, XbaI in crh7sense. After 
agarose gel electrophoresis fragments of 0.1 to 0.8 kb were extracted from the gel, 
digested and ligated into a pBluescriptSK vector. DNA sequencing was performed by 
the dideoxy chain termination method (38).
Cloning of tilapia CRH precursor cDNA
The construction of the tilapia hypothalamus cDNA library was described 
before (20). The library containing 4x105 independent clones of cDNA in the EcoRI- 
XhoI sites of the Uni-ZAP XR vector was used. PCR was performed on this library 
for 35 cycles at 94°C x 45", 54°C x 30", 72°C x 180" with pBluescript T3sense and 
T7anti primers and with specific tilapia primers that were based on a small (0.1 kb) 
cloned and sequenced part of the initial PCR results: primer crh8anti 5' CGC GGA 
TCC TTG TTC CGC CCT GGA CAT 3' and crh9sense 5' CGC TCT AGA CTG CTC 
CGG GAG ATG ATG 3' with recognition site BamHI in crh8anti and XbaI in 
crh9sense. After agarose gel electrophoresis fragments of 0.4 to 0.6 kb were 
extracted from the gel, digested, ligated into a pBluescriptSK vector, and sequenced. 
Subsequently the original library was screened for full length tilapia CRH using the 
cloned PCR fragments as probes. The probes were 32P labeled by random priming 
according to standard procedures (37). Replica nitrocellulose filters of the tilapia
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hypothalamus Uni-ZAP XR library were screened at 42°C in 6 x SSC  as described 
before (20). Hybridization positive plaques were purified and pBluescript DNA was 
prepared by in vivo excision according to the manufacturers protocol (Stratagene). 
DNA was sequenced on both strands.
Computer analysis of CRH precursors and construction of a phylogenetic tree
The tilapia (Oreochromis mossambicus) CRH precursor presented in this 
study was compared with precursor sequences obtained from the EMBL database 
(Release 57). Accession numbers for CRH precursor sequences are: V00571, 
human (Homo sapiens); X03036, rat (Rattus norvegicus); J00803, sheep (Ovis 
aries); Y15159, pig (Sus scrota); J04116, white sucker 1 (Catostomus commersoni); 
X58784, white sucker 2 (Catostomus commersoni); S50096, South-African clawed 
toad 1 (Xenopus laevis). In addition, the CRH precursor sequence for South-African 
clawed toad 2 (Xenopus laevis) was taken from Stenzel-Poore et al. (40) and for 
sockeye salmon (Oncorhynchus nerka) from Ando et al. (2). Accession numbers for 
urotensin I precursor sequences are: M11671, common carp (Cyprinus carpio); 
AJ005264, rainbow trout (Oncorhynchus mykiss), and for urocortin precursor 
sequences are: AF038633, human (Homo sapiens); AF038632, house mouse (Mus 
musculus); U33935, rat (Rattus norvegicus). Nucleotide sequences were translated 
into peptide precursors and multiple sequence alignments for the nucleotide and the 
peptide precursors were performed using the PileUp program from the GCG 
package (18). Minor adjustments in the aligned sequences of the CRH precursors 
were made manually to minimize gaps. Phylogenetic trees for the full CRH peptide 
precursors were constructed using a number of different methods: neighbor-joining 
(36), protein parsimony (13), Fitch-Margoliash (16), maximum likelihood (1). Trees 
were calculated using the programs PROTDIST, NEIGHBOR, PROTPARS and 
FITCH from the PHYLIP package (14). A total of 100 bootstrap samples were 
created using SEQBOOT and PROTDIST, reconstructed with NEIGHBOR, and 
subsequently analyzed with the CONSENSE program to construct the majority-rule 
consensus tree. Maximum likelihood trees were constructed using the program 
PROTML from the MOLPHY package (1) and PUZZLE (42).
Synthesis and purification of the mature tilapia CRH 41-residue amidated 
peptide
Tilapia CRH peptide was synthesized using solid-phase methodology, purified 
by preparative reserve-phase HPLC, and subsequently desalted and lyophilized 
according to Rivier et al. (34).
Bioassay: Pituitary superfusion
Mature tilapia of both sexes were obtained from our laboratory stock and kept 
in freshwater at 22 °C on a neutral background under 12L/12D light regime. The 
body weights of the fish were 33.1g ± 3.5 g (n = 33). The animals were fed daily with
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tropical fish food (Tetramin). Feeding was stopped 24 h before the superfusion 
experiments started. On the day of the superfusion, fish were quickly netted and 
sacrificed by spinal transection. Pituitary glands were dissected from the brain. Each 
gland was placed on a filter on the bottom of a superfusion chamber (volume 20 l^). 
Superfusion was performed as described previously (6), with slight alterations of the 
superfusion medium content (addition of ascorbic acid 1 mg/l as an antioxidant) and 
the superfusion flow rate (30 l^ /min). Pituitaries were pulsed for 40 min with either 
superfusion medium, tilapia CRH, or rat CRH; the latter two at a concentration of 10-7 
M previously shown to give maximal response in mammalian and fish systems (5, 
26, 32, 34, 46). CRH was dissolved in superfusion medium. Medium fractions of 10 
or 20 minutes were collected and stored at -20 °C until assayed for ACTH and a- 
MSH.
The ACTH and a-MSH release rates were tested against the prepulse release 
during reference period 90 min to 110 min. As described earlier (6) this prepulse 
release was set at 100% to overcome the increase in spontaneous ACTH release. 
Prepulse ACTH release rates were 1.49 ± 0.26 pg/min/pituitary (n = 33) and prepulse 
a-MSH release rates were 8.99 ± 0.23 pg/min/pituitary (n = 33).
Radio Immuno Assays
Tilapia ACTH was measured by RIA as described earlier (6) using an 
antiserum raised against ACTH1-24 kindly donated by Dr. R.M. Dores (Denver, 
Colorado). The a-MSH immunoreactivity was measured by RIA as described 
previously (7).
Statistics
All data are presented as mean ± SEM. To test differences between time 
points and the experimental groups, data were analyzed by the Mann-Whitney U- 
test; P < 0.05 was accepted as level of significance.
Results 
Tilapia CRH precursor cDNA
PCR with degenerate primers crh7sense and crh6anti on tilapia brain RNA 
and on liver genomic DNA yielded one (0.1 kb) fragment that was ligated into 
pBluescriptSK vector and sequenced. The fragment represented CRH amino acids 7 
to 35 and therefore was used as a 32P labeled probe to screen the tilapia 
hypothalamus Uni-ZAP XR cDNA library, but this did not result in positive clones. 
Other PCR fragments ranging from 0.1 to 0.8 kb did not code for CRH or CRF-like 
sequences.
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ggcacgagaagtgaaggagggcggcatctcgccaactacctggcaacctacacggctgta
gcggaccacctctaaagcctgaagattcctgttgaaatcctgacatgaagctcaatttat
M K L N L F
tcggtaccaccgtgattctgctagttgccttcttaccgcgctacgaatgtcgggctattg 
G T T V I  L L V A F L P R Y E C R A I E
agagccctggcagtactctgcgcgtcccagctctacaaacccaaaactcccagcagcagc 
S P G S T L R V P A L Q T Q N S Q Q Q Q
aatccggcccgattctggagaggcttggggaggagtatttcatccgactgggcaacgggg 
S G P I L E R L G E E Y F I  R L G N G D
actcgaactctttcccatcaacgtccatgtatcccggcggatcaccttccatcttcaaca 
S N S F P S T S M Y P G G S P S I F N R
gagctttgcaactccagctgacgcggcgtcttttacagggcaaagttgggaacatcaggg 
A L Q L Q L T R R L L Q G K V G N I R A
cgctcataagcggcttcggagaccgcggggacgactcgatggagaggggaagaaggtccg 
L I S G F G D R G D D S M E R G R__R S E
aggacccgccgatatccctggatctgaccttccacctgctccgggagatgatggagatgt 
D P P I  S L D L T F H L L R E M M E M S
ccagggcggaacaactggctcagcaagcgcagaataacagaagaatgatggagctcttcg 
R A E Q L A Q Q A Q N N R R M M E L F G
ggaaatgatttcccagcccgccaaagatctcccttccctttctttttcttttactccttc
__K *
tgttgtgcatttttgccatcagcacaaaacatgctctgtacaatatagtgctgctttatc
actttattgtttatagctttaacctcaaactatggagcataaacgggcttgacttataat
gagccgattgtaccttgccatttcaatgttggtgtcagatctgtagagatatgccgttct
tcatatttgagatgaatacttttgtctaagacatgaattgcattcacaaaattggcattt
tgttttagattatgaatcactgtatttatgatatttatgtttgttaaataaacttatgtg
caaccagtaaaaaaaaaaaaaaaaaaaa
60 nt
120 nt
6 aa
180 nt
26 aa
240 nt
46 aa
300 nt
66 aa
360 nt
86 aa
420 nt
106 aa
480 nt
126 aa
540 nt
146 aa
600 nt
166 aa
660 nt
167 aa
720 nt
780 nt
840 nt
900 nt
960 nt
988 nt
Figure 1. Nucleotide (nt) sequence of a tilapia hypothalamic CRH cDNA clone and the 
deduced amino acid (aa) precursor sequence.
The three amino acid sequence boxes that are conserved in all CRH sequences analyzed to date are 
presented in bold capitals (see text for explanation). Note the processing signals (underlined) at the 
amino and the carboxyl termini of CRH: a prohormone cleavage site (RR) and the typical (GK) 
residues for cleavage and amidation. The asterisk (*) represents the stop codon, and the 
polyadenylation signal (aataaa) is underlined. Accession number at EMBL nucleotide sequence 
database for tilapia CRH is AJ011835.
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Based on the sequence of the 0.1 kb PCR fragment, specific tilapia CRH 
primers crh8anti and crh9sense were combined with pBluescript primers T3sense 
and T7anti in a PCR on a tilapia hypothalamus cDNA library. This PCR resulted in 
expected fragments of 0.4 to 0.6 kb which, after cloning and sequencing, 
corresponded to the respective 5'-CRH and CRH-3' sequences of the tilapia cDNA 
(not shown). Finally the 5'-CRH and CRH-3' PCR clones were used as 32P labeled 
probes to screen the cDNA library, which yielded two hybridization-positive clones 
out of 106 amplified plaques. Following sequencing, the cDNA sequences were 
found to be identical between the two clones.
Figure 1 shows the nucleotide sequence (988 nt) of a tilapia hypothalamic 
CRH cDNA clone and the deduced amino acid sequence (167 aa) of the precursor 
protein. The translated tilapia CRH precursor includes the signal peptide (box I: nt 
105-176, aa 1-24). This sequence is followed by the cryptic peptide which contains a 
conserved motif (26) from amino acids 53 to 65 in tilapia (box II: nt 261-299). The 
mature tilapia CRH peptide (box III: nt 477-599, aa 125-165) is located between 
processing signals RR and GK.
Precursor CRH cDNA coding sequences (left) and mature CRH 1-41 translated amino acid 
sequences (right) of tilapia (Oreochromis mossambicus), two other teleost fishes (sockeye salmon, 
Oncorhynchus nerka; white sucker, Catostomus commersoni), and an amphibian (South-African 
clawed toad, Xenopus laevis) are compared with those of the rat. Numbers represent percentages of 
identity for the signal sequence, the conserved motif (box II) and the CRH coding region (left), and for 
the CRH peptide (right), relative to the rat CRH sequence. Only amino acids different from rat CRH 
are indicated.
Figure 3 (on opposite page). Alignment of ten CRH precursors with two urotensin I 
and three urocortin precursors.
Dots indicate gaps which have been introduced to achieve maximum identity. Black boxes indicate 
amino acids identical in at least six out of ten CRH sequences. In this CRH alignment, positions 1-24 
indicate the signal peptide sequence, positions 68-80 box II, and positions 158-198 the mature 
peptide. Potential cleavage sites are as indicated in Figure 1 for the tilapia CRH precursor. For details 
on accession numbers and references, see Materials and Methods.
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Comparison of CRH precursor cDNA sequences and mature peptides
CRH precursors of tilapia (501 nt) and of three other species (sockeye salmon 
(2), 501 nt; white sucker (29), 486 nt; South-African clawed toad (40), 486 nt) have a 
considerable degree of nucleotide identity relative to the rat (561 nt) sequence (23) 
(Figure 2, left panel). In comparison to the signal sequence of tilapia the identity with 
the signal sequence of white sucker is 75% and with that of sockeye salmon is 85%. 
Comparison of tilapia with its respective sucker and salmon counterparts, reveals 
72% and 80% identity for box II, and 78% and 80% identity for the CRH coding 
region.
The right panel in Figure 2 shows that the predicted tilapia CRH and salmon 
CRH peptides display the lowest degree of identity (76%) relative to rat CRH. Even 
less identity is found between tilapia and clawed toad (68%) and between tilapia and 
sheep (63%) CRH (17). Comparison of tilapia CRH peptide with sucker and salmon 
CRH in both cases reveals 80% identity.
Alignment and phylogenetic tree of CRH peptide precursors
Comparison of a multiple sequence alignment for ten CRH peptide precursors 
with two urotensin I and three urocortin precursors (Figure 3) reveals that box II in 
the cryptic peptide is absent in the urotensin I and urocortin precursors. The signal 
peptides of urotensin I and urocortin precursors differ in length and in most of the 
amino acid residues from the aligned signal peptide of CRH precursors. Notably, the 
tilapia CRH and salmon CRH mature peptides (41 aa) display 2 sequential 
methionines in amino acid residues 18-19 (positions 175-176 in Figure 3). Until 
recently, the stretch between aa 9 and 21 was considered a conserved region (28).
The alignment for the ten CRH precursors has led to the construction of 
phylogenetic trees, using different methods, which all show a topology with the 100% 
bootstrap values as presented in Figure 4. This representative unrooted consensus 
tree was constructed using the Fitch-Margoliash method with calculated PAM 
distances (14). The CRH precursors of tilapia, sockeye salmon and white sucker 1 
and 2 can be distinguished as a monophyletic group, with a high percentage of 
likelihood (96%) to cluster tilapia with salmon within this group. All methods 
distinguished CRH precursors of clawed toad 1 and 2 as another group distinct from 
the mammalian CRH precursors, but these different methods display a variation in 
branching pattern within the mammalian group.
CRH bioactivity
Within 10 min after addition of tilapia CRH or rat CRH peptide, pituitaries 
released more ACTH (Figure 5A) in comparison to the prepulse release rates (tilapia 
CRH P < 0.05 and rat CRH P < 0.001). The melanotrope cells (Figure 5B) reacted 
within a similar timeframe to tilapia CRH (P  < 0.02), whereas rat CRH did not evoke 
a stimulation until 10 min later (P  < 0.001).
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Maximum ACTH secretion was reached 10 min after termination of CRH 
administration (t= 155 min). Stimulation by tilapia CRH or rat CRH resulted in similar 
peak ACTH levels (368 ± 68 %  and 355 ± 60 %  respectively). In comparison to 
levels at the reference period (90 to 110 min) the unstimulated controls displayed a 
52 ± 8 %  increase (P  < 0.001) after 155 min. This increase in basal ACTH release is 
significantly lower than the increase in ACTH release after stimulation with either 
tilapia CRH (P  < 0.0005) or rat CRH (P  < 0.002).
A similar time pattern was observed for the CRH stimulation of a-MSH 
release, albeit that the maximum response to tilapia CRH (290 ± 31 % ) was 
marginally higher than that to rat CRH (247 ± 21 %). The a-MSH/ACTH release 
ratios of pituitaries before (9.9 ± 1.1, n = 33), and during maximal CRH stimulation 
were similar (9.9 ± 1.1, n = 10 for tilapia CRH and 8.7 ± 1.3, n = 11 for rat CRH).
Figure 4. Unrooted phylogenetic tree.
Phylogenetic tree representing the CRH peptide precursors of three teleost (tilapia, sockeye salmon, 
white sucker), one amphibian (South-African clawed toad) and four mammalian species. Numbers in 
branches represent the percentages of likelihood supporting a given branch in 100 bootstrap 
samples, calculated with the Fitch-Margoliash method. Only bootstrap values of more than 95% are 
presented in the figure. Bootstrap values for the branches in this tree after rat and human CRH 
precursor have branched off are 75% and 61%, respectively.
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Figure 5. Stimulation of ACTH (left) and a-MSH (right) release from tilapia pituitaries in 
vitro by tilapia CRH (A ) or rat CRH (□).
In both cases 10 M of CRH was used. During the pulse no CRH was added to superfusion medium 
of unstimulated pituitaries ( • ) .  Symbols and lines in the figure were slightly off-set to facilitate 
presentation of the error bars.
Discussion
Tilapia CRH precursor
The cDNA encoding the full CRH precursor sequence from tilapia is the third 
teleost and the fourth non-mammalian CRH sequence presently known. Our 
conclusion that this sequence represents the tilapia CRH is based on three findings. 
Firstly, the full tilapia precursor sequence contains a signal peptide, the CRH region 
with the cleavage and amidation sites, and the conserved motif (box II) typical for 
CRH precursors (26). Secondly, the tilapia CRH sequence is distinctly grouped 
within the CRH precursors in the phylogenetic tree, and not within the urotensin I 
precursors (not shown). Thirdly, comparison of the sequence of the mature tilapia 
CRH peptide with other representatives of the CRF superfamily confirms the identity 
of the peptide: tilapia CRH displays 80% and 76% amino acid sequence identity to 
white sucker CRH and rat CRH, respectively. The degree of identity of tilapia CRH to 
the members of the urotensin I/ urocortin lineage from these species is 54% (white 
sucker urotensin I) and 43% (rat urocortin) (47).
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The signal peptide sequence of the tilapia CRH precursor has the 
characteristic composition of secretory proteins, with a central hydrophobic region, 
and a cleavage site in agreement with the (-3,-1)-rule (50). Previously it was 
proposed (39, 17, 23) that the signal peptide of CRH precursors terminates at 
residues with a small neutral side chain. Therefore, the tilapia CRH signal peptide 
most likely terminates at either alanine (position 24) or serine (position 27). The 
cryptic peptide in tilapia, as in human and sheep (39, 17), contains a pair of basic 
residues (RR, positions 94-95 in Figure 1) which could function as a possible extra 
cleavage site. The cryptic peptide of all CRH precursors, including tilapia, contains a 
highly conserved 13 amino acid motif (box II) which does not feature in other 
precursors of the CRF superfamily (26). In comparison to the rat, the box II of both 
tilapia and white sucker contains two changes which are considered conservative 
(Leu for Met and Ile for Leu). This is not the case for the last residue (Gly in tilapia, 
Arg in sucker, and Leu in rat). Despite its presence in all CRH precursor sequences 
to date, the function for the cryptic peptide (or for the conserved motif) is yet 
unknown.
Mature tilapia CRH peptide is cleaved from the precursor between the dibasic 
(RR) potential cleavage site for prohormone convertases PC1 and PC2 at the amino- 
terminus, and the GK residues for cleavage and amidation at the carboxy-terminus. 
As for sockeye salmon (2), white sucker (29), clawed toad (40) and mammalian CRH 
(39, 17, 23), the C-terminal nonpolar residue phenylalanine of the mature tilapia 
CRH peptide is probably amidated during processing. The last residue differs 
between the CRH-like sequences. However, since this residue in all cases is a 
nonpolar amino acid (Ile, Ala, Val or Phe), this variation probably does not alter 
peptide function.
Phytogeny
The phylogenetic tree based on all full CRH peptide precursors presently 
known results in three monophyletic groups: the mammalian, the amphibian and the 
teleost CRH precursors. Initially (26, 27), a division of the CRH peptides into two 
groups was proposed, based on substitutions in the 41 amino acid sequence of the 
mature peptide. The first group would consist of human, rat and porcine CRH, the 
teleost white sucker CRH and the amphibian clawed toad CRH, because of the high 
identity of these peptides (93-100%). The second group would then be formed by 
CRH peptides of ruminant ungulates (sheep, goat, cow), which have a lower identity 
of 80-83% to the first group (26, 27). Presently, the tilapia and sockeye salmon 41 
amino acid sequences suggest the presence of more groups, because of their lower 
identity to both the first group (68-80%) and the second group (63-66%).
Theoretically, analyses of amino acid substitutions in full precursors yield 
more relevant information on the molecular phylogeny of CRH in comparison to 
analyses of substitutions in selected parts (such as the mature peptide), although the 
latter approach will generally include more species (26, 28). Overall, our
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phylogenetic relationships revealed by the analysis of CRH precursors agrees with 
the mammalian/ amphibian/ teleost relationships reported previously, following 
similar analyses of the vasopressin/ vasotocin and the oxytocin/ isotocin precursors 
(21), the gonadotropin releasing hormone (GnRH) precursors (19), and the 
proopiomelanocortin (POMC) precursors (4), but within the teleost group some 
variation in subgroups is found. It is of interest that the CRH precursor of tilapia 
(superorder of Acanthopterygii) is clustered more closely with sockeye salmon 
(Protacanthopterygii) compared to white sucker (Ostariophysi), whereas in the case 
of the GnRH precursors the more advanced teleosts (Acanthopterygii) are grouped 
separately from the less advanced salmonids (Protacanthopterygii) and from the 
catfish (Ostariophysi) (19). More information about other teleost CRH precursors will 
further clarify phylogenetic relationships within this group.
CRH 1-41 peptide
The tilapia CRH sequence and the sockeye salmon CRH sequence prove that 
more variation exists between orthologous vertebrate CRH structures, and teleost 
CRH structures in particular, than previously recognized. In comparison to rat CRH, 
both tilapia and salmon CRH display 10 amino acid differences, which however are 
not similarly distributed over the N-terminal (CRH 1-17) and the C-terminal (CRH 18­
41) region. These two regions each contain a strongly conserved sequence, but 
differ in their sensitivity to single-point amino acid replacements with respect to 
receptor binding and activation of ACTH release (9, 24). In the case of tilapia 9 out of 
10 amino acids different from rat CRH are located in the 18-41 region, whereas in 
salmon CRH the differences with rat CRH are almost equally distributed over the N- 
and C-terminal region. The N-terminal region of CRH was found to be highly 
sensitive to single-point amino acid replacements (9, 24), but the consequences of 
the amino acid differences in salmon CRH for the ACTH releasing potency are as yet 
unknown. White sucker CRH differs from rat CRH only in 2 positions at the C- 
terminal end.
Although most of the amino acid differences in tilapia CRH peptide are 
conservative, in particular two characteristics might have implications for its 
bioactivity. First, the multiple methionine residues in fish CRH are particularly 
notable: three methionine residues in white sucker, five in tilapia and six in salmon 
against one in sheep and two in rat CRH. At the time of the discovery of ovine CRH, 
the oxidation of one methionine residue present in this peptide was associated with a 
tenfold loss of biological potency (46). As it was thought that this oxidation was an 
artefact of the extraction or purification method of native ovine CRH, rat CRH was 
isolated from hypothalamic extracts in the presence of reducing agents (34). 
Subsequently, native rat CRH was shown to have a potency similar to that of 
synthetic rat and synthetic ovine CRH in stimulating ACTH secretion (34). On the 
basis of these findings we decided to use ascorbic acid when testing the bioactivity 
of tilapia CRH. A median eminence is absent in teleost fish, which may indicate that
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CRH and other neuropeptides with multiple methionine residues in teleosts are less 
susceptible to oxidative agents in vivo than in other vertebrates. One might speculate 
that vertebrates that possess a pituitary portal system may have had to deal with 
some pressure on the presence of these oxidation-sensitive methionine residues in 
CRH. The second characteristic of tilapia CRH that may bear consequences for 
mechanisms of action are the differences with ovine CRH at positions 18, 25, 33 and 
40. In a conserved amino acid replacement study (9), four from the six ovine CRH 
analogs which showed a dramatic increase in receptor binding affinity concerned 
amino acid differences at one of these four positions. This increase in receptor 
binding affinity displayed by the CRH analogs was not accompanied by an increase 
in ACTH releasing activity in comparison to synthetic ovine CRH (9).
Synthetic tilapia CRH and rat CRH appeared equally potent in the stimulation 
of tilapia corticotropes and melanotropes. Previous studies reported similar 
potencies for white sucker CRH and rat CRH in stimulating ACTH release from 
superfused goldfish anterior pituitary cells (26). Maximal ACTH response in the 
tilapia bioassay was several fold higher than in the goldfish bioassay, which 
produces maximally an 80% increase. However, this difference cannot be explained 
by the use of a homologous versus a heterologous bioassay (because in both cases 
rat CRH was used as a reference), but is likely caused by differences in pulse time, 
superfusion conditions and test species. Trout pituitaries also respond with a large 
maximal increase in ACTH release to stimulation with rat CRH (5, 32), but no data 
are available for sockeye salmon CRH bioactivity in a salmonid bioassay. We 
suggest that the 260% ACTH increase observed in the tilapia bioassay resembles 
the magnitude of an in vivo stimulation. In trout, plasma ACTH levels increase 450% 
after handling and confinement stress (43). After a more severe restraint and 
confinement stress also the trout melanotropes are stimulated which results in a 
rapid 10-fold increase in plasma a-MSH levels (43), although the relationship 
between stress and plasma a-MSH is less unequivocal than that with plasma ACTH
(7). In some amphibians and fish, a-MSH exerts more functions such as the 
adaptation to a light or dark background (20, 48). Stimulation of neurointermediate 
lobe tissue of Xenopus laevis or goldfish in vitro with ovine CRH was found to give a 
maximal 100% or 50% increase in a-MSH secretion, respectively (48, 45). As in the 
case of ACTH, the maximal increase in a-MSH release (190%) was several times 
higher in the tilapia bioassay than in the goldfish bioassay.
Notwithstanding the equipotency of teleost and rat CRH in pituitary bioactivity, 
other CRH functions may be affected by the difference in structure of the peptides. 
CRH exerts its various actions through two receptor types, CRH-R1 and CRH-R2 
(47, 3). The abovementioned pituitary dependent actions of CRH generally are 
considered to be CRH-R1 mediated (47). After the initial focus on the effects of CRH 
in stimulation of the pituitary-adrenal axis, more recently the pituitary-adrenal 
independent or central actions of CRH, mediated through the CRH-R2 receptor, 
have attracted biomedical interest. In humans, long-term inappropriate neuronal
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control by CRH may manifest itself in a number of psychiatric illnesses including 
chronic depression, anxiety disorders, anorexia nervosa and Alzheimer’s disease (3,
8). Also in fish, CRH is likely to be involved in central regulations, such as feeding 
behaviour, as intracerebroventricular CRH treatment results in reduced appetite in 
goldfish (12). Consistent with the suggestion that the differences between tilapia and 
rat CRH might result in different functions of CRH, preliminary findings using 
membranes from MEL cells transfected with CRH-R2 showed that the two peptides 
display different binding affinities for the CRH-R2 receptor (D.J. Tellam et al., 
unpublished results; 31). Differences in structure between CRH peptides from lower 
and higher vertebrates may relate to the evolution of different regulatory functions of 
CRH. Notably, the role of CRH as a principal coordinator of both thyroid and 
interrenal axes during specific developmental stages in amphibians and fishes (25) 
has been lost during evolution. Further comparative research on CRH physiology 
using homologous peptides may clarify our understanding of the pituitary-interrenal/ - 
adrenal dependent and independent actions of CRH.
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CHAPTER 7
Bacterial lipolysaccharides 
and the CRH response during stress
in the teleost fish 
Oreochromis mossambicus (tilapia)
F.H.J. van Enckevort, P.P.L.M. Pepels, 
P.H.M. Balm, S.E. Wendelaar Bonga
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Abstract
This study describes the effects of injection of lipopolysaccharide (LPS) 
preparations from Escherichia coli and Vibrio cholerae on the activation of the 
hypothalamus-pituitary-interrenal (HPI) axis in tilapia (Oreochromis mossambicus), 
with confinement as an additional stressor. The quantitative analysis of the 
distribution of corticotropin-releasing hormone (CRH) in the fish brain in response to 
the bacterial endotoxin challenges revealed that in particular E. coli LPS appeared to 
modulate the response of tilapia to confinement stress with higher diencephalic CRH 
and lower pituitary CRH levels. As changes were also noted in osmoregulatory, 
metabolic and neuroendocrine parameters, we suggest that crosstalk between the 
activated immune system and the neuroendocrine system occurred at multiple levels 
of organisation in our fish. It remains to be established to which extent CNS CRH is 
involved in regulating these parameters in this species, but conceivably the role of 
CRH in immune-endocrine interactions is a phylogenetically old principle.
Introduction
Throughout the vertebrates corticotropin-releasing hormone (CRH) plays a 
pivotal role in the neuroendocrine stress response (7). In fish, as in mammals, the 
neuropeptide stimulates the release of ACTH, which in turn leads to a surge in 
circulating corticosteroids. Conversely, it has been shown that experimental 
treatment with corticosteroids negatively affects the release of CRH from nerve 
terminals located in the median eminence (mammals), or in the pituitary in the case 
of fish (13, 19). Intimately connected to its role in the regulation of the activity of the 
hypothalamus-pituitary-adrenal (HPA) axis in mammals and the hypothalamus- 
pituitary-interrenal (HPI) axis in fish, the neuropeptide CRH also exerts actions 
related to growth, reproduction and the immune system.
Despite the apparent degree of similarity regarding some of the actions of 
CRH between the vertebrate phyla, more variation exists between CRH molecules 
than previously recognised, as was recently shown on the basis of the sequence of 
salmon (1) and tilapia (20) CRH molecules. In addition, the distribution of CRH in the 
CNS of tilapia exhibits some remarkable features, which have not been 
demonstrated in higher vertebrates. Among these are prominent cell groups and 
projections in the teleost forebrain (15). The question arises whether these unique 
characteristics of the CRH system in fish exemplify functions that deviate from the 
known (mammalian) pattern. The present study addresses the possible involvement 
of CRH in the communication between the neuroendocrine and the immune system 
in the teleost fish Oreochromis mossambicus (tilapia).
Previously it has been demonstrated for fish that neuroendocrine factors 
modulate the activity of the immune system and, conversely, that activation of the
102
immune system bears consequences for the neuroendocrine system (for Reviews: 5,
9). Whether these interactions are facilitated through common messengers and 
receptors used by the two regulatory systems in fish (to the extent demonstrated for 
mammals) remains to be established. Nevertheless, stimulation by 
lipopolysaccharide (LPS) of the release of ACTH and a-MSH immunoreactivities 
from teleost immune tissues has been reported (2, 4), and cortisol receptors have 
been demonstrated on fish leucocytes (12). In vivo treatment of tilapia with LPS from 
Escherichia coli resulted in modulation of the activity of the hypothalamus-pituitary 
interrenal (HPI) axis at the level of the cortisol producing tissue, which became 
markedly less responsive to ACTH (4). To date there is no information available 
concerning the effects of these treatments on the CRH producing system in fish. We 
have treated tilapia with LPS preparations from E. coli and Vibrio cholerae, and here 
we report effects observed in fish sampled either before, or following 24h 
confinement. Emphasis was placed on a quantitative analysis of the brain and 
pituitary CRH contents. Furthermore, plasma cortisol, glucose and chloride levels 
were assessed. The osmoregulatory consequences of stressful conditions vary 
markedly between fish and mammals and could point to actions of CRH that are 
specific for fish.
Materials and Methods 
Animals
Forty-eight tilapia (Oreochromis mossambicus) of mixed sex from our 
laboratory stock were equally distributed between three 120 litre aquaria of neutral 
background. Water was continuously aerated, filtered (Eheim) and refreshed (10 l/h). 
Water temperature was 25°C, light/dark regime was 12L/12D, and fish were fed 
twice daily with Tetramin tropical fish food at a daily rate of 1.5% (w/w) of their body 
weight.
Fish were left undisturbed in their aquaria for 4 weeks. To obtain samples 
(n=12) from undisturbed fish, on 4 alternate days one fish from each aquarium was 
quickly netted and sampled for blood and brain tissue (pre-injection samples). On 
each of these four days aquaria were sampled in random order and sampling was 
completed within two minutes. Blood was collected in tubes with EDTA (1.5 mg/ml) 
and aprotinine (3000 KlU/ml; Trasylol, Bayer AG, Leverkusen, Germany). Collected 
blood was centrifuged, and plasma was separated and stored at -20°C until 
analyses. Following spinal dissection, fish were weighed and sexed, fork length was 
measured, pituitary and brains were removed, and the tissue samples were frozen at 
-20°C until analyses. Starting two days after taking the final pre-injection samples, 
the remaining 12 fish per aquarium were injected intraperitoneally either with saline, 
with 3 mg/kg body weight E. coli LPS (Sigma, serotype 0111:B4, lot # 110K4060), or 
with 3 mg/kg body weight V. cholerae LPS (Sigma, serotype Inaba 569B; lot #
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78H4038). Fish were injected on three alternate days. One day following the final 
injection 6 fish were sequentially sampled from each aquarium (pre-confinement). 
Sampling of the three groups was completed within 35 minutes. The remaining 6 fish 
per aquarium were placed in nets (confinement in approximately 1 litre of water 
volume) in their home aquarium, and were sampled 24h later (also within 35 
minutes).
Sample treatment and assays
Pituitary and brain samples were treated as described by Pepels et al. (16), 
with the exception of the dissection into various brain parts (see Figure 1). CRH 
levels in the tissue extracts were measured by RIA (16), and expressed as pg CRH 
per tissue. Plasma cortisol was assayed by RIA (3), plasma glucose was measured 
using a commercial kit (Boehringer Mannheim, Germany), and chloride was 
quantified by flame photometry.
Figure 1. Saggital overview of the brain of Oreochromis mossambicus (tilapia)
The overview shows the dissected parts (telencephalon, diencephalon, rhombencephalon, and 
pituitary) and their CRH contents in pg per tissue (n=12; pre-injection values of undisturbed fish). The 
hatched areas indicate brain parts which were discarded: tectum and midbrain, and the rostral part of 
the spinal cord.
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Presentation of data and statistics
As there were no differences between groups regarding the pre-injection 
samples, these values were pooled to yield n=12. Values presented are means ± 
SEM  (n-1). The condition (K) factor of the fish was calculated from 100 w/l3 (w = 
body wet weight; l = fork length). Differences between treatments were assessed by 
Student’s T-test (2-sided), and P<0.05 was accepted as indicative of significant 
differences. Differences between saline and LPS treatments in the pre-confinement 
samples are indicated by a letter code (samples sharing similar letters are not 
significantly different), whereas confinement effects within a saline or LPS treatment 
group are indicated by an asterisk.
Results
Throughout the experiment, the feeding response remained unaltered, and 
none of the fish died as a result of the experimental treatment. Results presented in 
Figure 1 demonstrate that in fish that were sampled before the start of the injection 
procedure, the telencephalon contained the highest amounts of CRH. Substantial 
amounts of CRH were also recovered from the diencephalon, containing the 
hypothalamus, and the rhombencephalon, containing the vagal lobe. In comparison, 
the pituitary contained surprisingly low amounts of CRH (about one third of the 
amount of CRH found in the diencephalon). Total CRH levels in the pituitaries and 
brains of each of these 12 fish amounted to approximately 5 ng.
There were no differences between saline and LPS treatment groups 
regarding body weight, K factor or plasma parameters in fish sampled one day 
following the final injection with saline or LPS (Table 1), with the exception of the 
hypoglycaemia observed in the E. coli treated fish. In the saline and LPS treatment 
groups the 24h confinement evoked changes, which differed between treatments. In 
the saline group plasma glucose and cortisol were elevated after 24h confinement, 
whereas in the E. coli LPS treated fish plasma glucose was elevated and plasma 
chloride was decreased after confinement. None of these variables was altered by 
confinement in V. cholerae LPS treated fish. Overall, the injection and sampling 
protocol appeared to induce elevations in plasma glucose and plasma cortisol in 
comparison to samples from undisturbed fish (pre-injection control values).
In comparison to saline treatment, fish treated with V. cholerae LPS, but not 
with E. coli LPS, exhibited higher CRH levels in the telencephalon and in the 
diencephalon (Figure 2). Fish treated with E. coli LPS however displayed 
confinement-induced increase in CRH content in the diencephalon and decrease in 
CRH content in the pituitary, changes which were not observed in saline treated fish.
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Table 1. Physiological parameters assessed in saline treated fish, and in fish treated 
with either V. cholerae or E. coli LPS.
Saline V. cholerae LPS E. coli LPS
pre­
confinement
(6)
24 h 
confinement 
(6)
pre­
confinement
(6)
24 h 
confinement 
(6)
pre­
confinement
(6)
24 h 
confinement 
(6)
body weight 43.4 ± 4.3 a 44.5 ± 5.8 38.9 ± 2.1 a 39.7 ± 1.8 38.9 ± 2.2 a 38.8 ± 5.1
K factor 1.69 ± 0.03 a 1.61 ± 0.03 1.64 ± 0.03 a 1.62 ± 0.05 1.57 ± 0.04 a 1.64 ± 0.03
plasma glucose 61 ± 3 a 85 ± 5 * 62 ± 7 a 82 ± 8 49 ± 5 b 106± 10 *
plasma cortisol 141 ± 31 a 326 ± 39 * 162± 30 a 289 ± 46 222 ± 20 a 331 ± 28
plasma chloride 134 ± 3 a 128 ± 4 135± 3 a 128 ± 4 135 ± 2 a 120 ± 4 *
The treatment groups were sampled before (pre-confinement) or following 24h confinement. Numbers 
of fish per group are indicated between brackets. Parameters of undisturbed fish (12 pre-injection 
control samples) are 39.2 ± 3.0 for body weight (g), 1.65 ± 0.04 for condition (K) factor (100 w /l), 40 ± 
4 for plasma glucose (mg/100ml), 4 ± 1 for plasma cortisol (ng/ml), and 140 ± 2 for plasma chloride 
(mM). The letter code indicates differences between the saline and LPS treatments in the pre­
confinement groups (groups sharing similar letters are not significantly different), whereas the asterisk 
(*) indicates a confinement effect within a saline or LPS treatment group.
Discussion
In this study for the first time levels are presented of CRH in fish brain tissues 
in response to an external factor, in particular to a bacterial endotoxin challenge. The 
results indicate that in particular E. coli LPS modifies the reaction of tilapia to the 
additional stressor of 24h confinement. As this modification includes osmoregulatory, 
metabolic, endocrine and neurological parameters, we suggest that crosstalk 
between the activated immune system and the neuroendocrine system occurred at 
multiple levels of organisation in our tilapia.
No LPS effects were observed on fitness, body weight, or on appetite of our 
fish demonstrating that these ectothermic animals are markedly less sensitive to LPS 
than mammals, where similar doses would have been lethal (21). The 
hypoglycaemia in E. coli LPS treated tilapia confirms a previous observation (4).
Further research is needed to establish whether the increased CRH levels in 
brain sections observed in V. cholerae endotoxin treated fish relate to the 
pathogenicity of Vibrio spp. (11). Whereas these effects were restricted to non­
confined fish, E. coli endotoxin appeared to modulate the response to confinement 
with higher diencephalic CRH and lower pituitary CRH levels. Conceivably, such 
effects could well influence the ability of the animal to cope with additional 
environmental stressors.
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Figure 2. Effects of injection with Saline, V. cholerae LPS, or E. coli LPS on brain and 
pituitary tissue CRH levels in tilapia (n=6 in all cases).
Open bars indicate pre-confinement values and solid bars indicate values of fish sampled following 
24h confinement. The letter code indicates differences between the saline and LPS treatments in the 
pre-confinement groups (bars sharing similar letters are not significantly different), whereas the 
asterisk (*) indicates confinement effects within a saline or LPS treatment group.
It should be taken into consideration that the total amount of CRH measured 
in a given tissue sample was extracted from cell bodies, axons, and nerve terminals. 
Furthermore, the dissection scheme employed resulted in samples which each 
contained multiple CRH containing regions. Hypothalamic CRH for instance forms a 
minor contribution to total diencephalic CRH (15, 16). Thus, the amount of CRH in 
each of the samples can not be related to a specific group of CRH-producing cells or 
a specific part of the brain. Moreover, the functional roles of the CRH regions 
identified in this species (15) have only partly been elucidated. For instance the 
tectum was not considered in this study as the physiological meaning of its CRH 
containing cell population is totally unclear at this stage. Because of these 
constraints, we cannot draw conclusions concerning the specific involvement of 
hypothalamic CRH producing neurons (or of CRH-containing nerve terminals
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innervating hypothalamic neurons) in the effects observed. The major conclusion 
from this work is that LPS treatment in tilapia exerts its influences at the level of the 
CNS CRH system. The drop in pituitary CRH content following confinement in E. coli 
treated fish, but not in saline treated fish, suggests that during stress in these LPS 
treated animals the release of CRH from pituitary nerve terminals was stimulated in 
comparison to the stressed saline treated animals. These CRH-containing terminals 
in tilapia are restricted to the rostral pars distalis and the pars intermedia, and 
consequently overlap with the distribution of the two pituitary POMC producing cell 
types. The observed drop in pituitary CRH content reflects enhanced release of CRH 
in this area and suggests stimulated a-MSH and ACTH release from the pituitary 
gland. CRH is an established secretagogue for a-MSH and ACTH in vertebrates, 
including fish (4, 20).
We consider the plasma cortisol values measured in our undisturbed fish, 
sampled before injection of saline or LPS, as the levels circulating in fish at rest. The 
high values reported here for all fish sampled following saline or LPS treatment 
should be interpreted with caution, as these may indicate inherently stressful 
experimental conditions associated with the injection and sampling protocol. It has 
been shown previously (3) that tilapia reacts extremely rapid (within a few minutes) 
to a perceived stressor, such as sampling, by elevating circulating cortisol levels over 
resting levels. Within ten minutes values level off, and we generally consider these 
plateau levels to indicate maximal levels attained as a result of sampling in 
combination with the preceding treatment. For determining the pre-injection control 
samples, one fish from each aquarium was taken on alternate days within 2 minutes, 
whereas for sampling of six fish from each treatment group from three aquaria 35 
minutes was needed. Therefore, the cortisol levels of the injection treatment groups 
represent plateau levels (mainly for fish samples 3-6) and do not indicate the cortisol 
levels circulating in the fish prior to sampling. Differences in plasma cortisol levels 
between treatment groups can therefore at best be interpreted to indicate modulation 
of stress responsiveness by these treatments. As such, the significant elevation of 
plasma cortisol in the reaction to confinement of the saline treated group, in contrast 
to lack of a significant elevation of plasma cortisol in the LPS treated groups, 
provides indirect evidence for modulation of the reactivity of the HPI axis by the LPS 
treatment.
It has been established that in teleost fish a homologue of interleukin-1 is 
expressed (8, 17). The same most likely applies for other cytokines as well (10). 
Importantly, the expression rate of IL-1 can be stimulated by LPS treatment in vitro 
and in vivo (6, 14, 17). Thus, fish possess the mechanisms to react to a bacterial 
infection with an activation of corticosteroid release via the routes established for 
mammals (LPS - IL-1 - CRH - ACTH). This could take place at the organismal level 
(via the pituitary ACTH cells) or in a paracrine fashion, as the release of ACTH-like 
immunoreactivity from fish leucocytes has been demonstrated (2). The biological 
significance of immune-endocrine mechanisms has been demonstrated in rats which
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are unable to elevate corticosteroid output in response to an immunological 
challenge. These rats develop rheumatoid arthritis as a result of insensitivity of their 
CRH-producing neurons to IL-1 (18).
It remains to be established to which extent CNS CRH is involved in 
regulating the various physiological parameters examined in our study of tilapia. It is 
clear from our results that LPS treatment can induce significant changes on CNS 
CRH. This suggests that the role of CRH in immune-endocrine interactions is a 
phylogenetically old mechanism. The previously established unique sequence of the 
tilapia peptide (20) and the atypical distribution of the CRH neurons (15) may not be 
fundamental from a functional point of view, at least for its actions related to the 
stress response, such as the regulation of the HPI axis.
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CHAPTER 8
Summary and Conclusions
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Summary and Conclusions
In this thesis the effects of infection, or injection of bacterial endotoxin, on the 
activity of the hypothalamus-pituitary-adrenal (HPA) axis in mouse and the 
hypothalamus-pituitary-interrenal (HPI) axis in fish were studied. Two key messenger 
molecules of the immune system and the HPA/HPI axis were central in this thesis: 
interleukin(IL)-6 and corticotropin-releasing hormone (CRH), respectively. In the 
mouse model, the role of IL-6 in the response of the immune system and the 
stimulation of the HPA axis was studied after infection with micro-organisms, and 
after injection of bacterial endotoxin. IL-6-deficient mice, which are unable to elicit a 
complete immune response upon infection, were used for this purpose. In the fish 
model, the bioactivity of rat and tilapia CRH was compared, and the distribution of 
CRH in tilapia brain was determined after injection of bacterial endotoxin.
In CHAPTER 1 a short introduction to the concept of stress is given. The 
concept of bi-directional communication between the neuroendocrine and the 
immune system during inflammation is introduced with information on interleukins, 
IL-6 in particular, and on CRH. Thereafter, information on the different infection 
models used in this thesis is presented. The research described in CHAPTERS 2 to
5 is focussed on the role of IL-6 in the response of a mammal to infection with micro­
organisms. The studies were performed in IL-6 deficient (IL-6-/-) mice and their wild 
type (IL-6+/+) controls. Three different infection models were used: Candida albicans 
(CHAPTER 2), Yersinia enterocolitica (CHAPTER 3), and Klebsiella pneumoniae 
(CHAPTER 4). After infection with one of these three micro-organisms the survival of 
the mice and the outgrowth of the micro-organisms in different organs were 
determined. Moreover, the possible role of IL-6 was investigated in the responses of 
the immune system and the HPA axis to infection, and to injection with purified 
endotoxin from Escherichia coli (CHAPTER 5). In the studies described in 
CHAPTERS 6 and 7, the role of CRH as central mediator of the HPI axis in teleost 
fish was investigated in Oreochromis mossambicus (tilapia). The tilapia CRH 
sequence was unraveled, its activity with respect to pituitary stimulation was 
determined (CHAPTER 6), and the responses of the HPI axis to confinement stress 
and to injection with endotoxin were investigated in tilapia (CHAPTER 7).
IL-6 is a multifunctional cytokine that regulates multiple aspects of the innate 
immune response. It has been shown before that endogenous IL-6 is crucial for an 
efficient defense against severe infections with Gram-negative and Gram-positive 
bacteria. The aim of the study described in CHAPTER 2 was to investigate the role 
of endogenous IL-6 in the defense against infection with the yeast C. albicans. We 
found that during experimental candidiasis, IL-6-/- mice had a decreased survival 
and an increased fungal load in their organs when compared with IL-6+/+ controls, 
despite increased plasma concentrations of the cytokines TNF, IL-1 a and IL-1 p. IL-6-
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/- mice were not able to mount an efficient neutrophil response during the infection. 
When mice were rendered neutropenic by cyclophosphamide, neutropenic IL-6+/+ 
mice were equally susceptible to C. albicans compared to neutropenic IL-6-/- mice, 
implying that neutrophils mediate the beneficial effect of endogenous IL-6. In 
conclusion, IL-6-/- mice are more susceptible to disseminated candidiasis than IL- 
6+/+ mice, and IL-6 exerts its effect most likely by neutrophils.
In CHAPTER 3 we investigated whether infection of IL-6-/- mice with the 
Gram-negative micro-organism Y. enterocolitica is also characterized by a lack of 
generation of infection-associated neutrophilia. Infection of IL-6-/- mice with Y. 
enterocolitica was characterized by a higher mortality than infection of IL-6+/+ mice. 
Despite the higher mortality, IL-6-/- mice did not harbor more bacteria in spleen, liver, 
kidneys or mesenteric lymph nodes than IL-6+/+ mice, and in contrast to findings in 
other infection models Yersinia-infected IL-6-/- mice were capable of developing a 
normal peripheral neutrophil response. Thus, our IL-6-/- mice were highly susceptible 
to Y. enterocolitica infection despite the generation of functional infection-associated 
neutrophilia. We conclude that the lack of a neutrophil response does not seem to be 
an intrinsic characteristic of IL-6-/- mice, but rather depends on the pathogen 
involved.
During bacterial infections both the immune system and the HPA axis are 
activated. The role of IL-6 in the activation of the HPA axis during bacterial sepsis is 
not fully understood. IL-6 is probably a pivotal cytokine in the interaction between the 
immune system and the HPA axis, but so far this had not been demonstrated 
unequivocally. The results with the third infection model we used to study both 
immune and adrenal responses in IL-6-/- and IL-6+/+ mice were presented in 
CHAPTER 4. The aim of this study was to investigate the role of endogenous IL-6 in 
the defense against a potentially lethal infection with K. pneumoniae, and in the 
concomitant stimulation of glucocorticoid release by the cortex of the adrenal gland. 
We demonstrated that IL-6-/- mice are more susceptible than IL-6+/+ mice to a 
systemic infection with K. pneumoniae, with a higher mortality and an increased 
outgrowth of micro-organisms in the liver, spleen and kidneys. We also found an 
impaired recruitment of peritoneal neutrophils. Moreover, this infection was 
associated with lower plasma corticosterone levels and with higher TNF levels in IL- 
6-/- mice than in IL-6+/+ mice. We conclude that IL-6-/- mice are very susceptible to 
Gram-negative bacterial infections, which is probably mainly due to an impaired 
recruitment of neutrophils to the site of infection in the absence of IL-6. Furthermore, 
the reduced adrenal response may explain the stronger inflammatory response with 
higher TNF plasma levels in IL-6-/- mice than in IL-6+/+ mice.
In CHAPTER 5 we investigated the role of IL-6 in the adrenal response in 
mice after injection with a single dose of purified LPS from E. coli. We examined the 
effects of intraperitoneal administration of LPS (range 0.25 - 2000 ^g/mouse) on 
plasma corticosterone, TNF and IL-1 levels in IL-6-/- and in IL-6+/+ mice. Plasma 
corticosterone levels increased within one hour after injection in both mouse strains.
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The corticosterone response was significantly reduced in IL-6-/- mice, but no 
differences in TNF or in IL-1 plasma levels were found between the two strains. 
Next, we studied the involvement of IL-1 or TNF in the responses of IL-6-/- and IL- 
6+/+ mice to LPS by chronic infusion of a recombinant human IL-1 receptor 
antagonist (IL-1 ra), or by injection of anti-TNFa antibodies, respectively. 
Pretreatment with IL-1 ra or with anti-TNFa did not affect the corticosterone response 
to LPS, neither in IL-6-/- nor in IL-6+/+ mice. In conclusion, our data suggest that 
lack of endogenous IL-6 in mice results in a reduced adrenal response to injection 
with a single dose of purified endotoxin. We conclude that IL-1 and TNF are not 
critically involved in the activation of the HPA axis after LPS administration in mice, 
and that IL-6 is important for the adrenal response to LPS.
From the studies described in CHAPTERS 2 to 5 of this thesis it can be 
concluded that:
1. IL-6-/- mice have a higher mortality than IL-6+/+ mice in all three infection 
models studied (C. albicans, Y. enterocolitica and K. pneumoniae), 
demonstrating that endogenous IL-6 is crucial for the survival of the mice 
during infection.
2. Increased concentrations of TNF and IL-1 in the IL-6-/- mice are not able 
to compensate for IL-6-deficiency with regard to protection against 
infection with C. albicans or K. pneumoniae.
3. An impaired neutrophil response seems to be responsible for increased 
outgrowth of pathogens in the organs of IL-6-/- mice during the first days of 
infection with C. albicans and K. pneumoniae.
4. Endogenous IL-6 is necessary for an adequate adrenal response to 
infection with K. pneumoniae and to injection with bacterial endotoxin from 
E. coli. In these two models, we found no evidence that the cytokines IL-1 
and TNF are critically involved in the activation of the HPA axis.
In CHAPTERS 6 and 7of this thesis we investigated the role of CRH, a central 
regulator of the response to a stressor, in the teleost fish tilapia. Although it was 
already clear that CRH is involved in the stress response in all vertebrate groups, 
only a limited number of studies on this neuroendocrine peptide had dealt with 
nonmammalian neuroendocrine systems.
In CHAPTER 6 we established the cDNA sequence of the CRH precursor of 
tilapia and studied the biological potency of the synthesized CRH peptide in a 
homologous teleost bioassay. Polymerase Chain Reaction with degenerate and 
specific primers yielded fragments of tilapia CRH cDNA. Full-length CRH cDNA (988 
nucleotides) was obtained by screening a tilapia hypothalamus cDNA library with the 
tilapia CRH PCR products. The deduced precursor sequence (167 amino acids) 
contains a signal peptide, the CRH peptide, and a motif conserved among all 
vertebrate CRH precursors. Tilapia CRH (41 amino acids) displays between 63%
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and 80% amino acid sequence identity with CRH from other vertebrates, whereas 
the degree of identity with members of the urotensin I / urocortin lineage is 
considerably lower. In a phylogenetic tree, based on alignment of all full CRH 
peptide precursors presently known, the three teleost CRH precursors form a 
monophyletic group distinct from amphibian and mammalian precursors. Despite the 
differences between the primary structures of tilapia and rat CRH, maximally 
effective concentrations of tilapia and rat CRH were equally potent in stimulating 
ACTH and a-MSH release by tilapia pituitaries in vitro. The teleost fish CRH 
sequences show that more variation exists between orthologous vertebrate CRH 
structures and teleost CRHs in particular than previously recognized. Whether the 
structural differences reflect different mechanisms of action of this peptide in the 
stress response remains to be investigated.
The aim of the study described in CHAPTER 7 was to investigate the role of 
CRH in the activation of the HPI axis in tilapia. We examined the effects of injection 
of LPS preparations from E. coli and Vibrio cholerae on the activation of the HPI axis 
in tilapia during basal conditions and during confinement as an additional stressor. 
The distribution of immunoreactive CRH levels in the fish brain, and the plasma 
chloride, glucose and cortisol levels were determined. The quantitative analysis of 
CRH in the brain in response to the bacterial endotoxin challenge revealed that in 
particular E. coli LPS modifies the reaction of tilapia to confinement stress. As this 
modification includes osmoregulatory, metabolic and neuro-endocrine parameters, 
we suggest that crosstalk between the activated immune system and the neuro­
endocrine system occurred at multiple levels of organisation in tilapia. It remains to 
be established to which extent CRH in the brain is involved in these regulatory 
mechanisms in this species, but conceivably the role of CRH in immune-endocrine 
interactions is a phylogenetically old mechanism.
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In dit proefschrift werden de gevolgen bestudeerd van een infectie, of van een 
injectie met bacterieel endotoxine, op de activiteit van de hypothalamus-hypofyse- 
bijnier (HHB)-as in de muis en de hypothalamus-hypofyse-kopnier (HHK)-as in de 
vis. Twee boodschapper moleculen van respectievelijk het immuunsysteem en de 
HHB/HHK-as stonden centraal in dit proefschrift: interleukine(IL)-6, en "corticotropin- 
releasing hormone” (CRH), het neuro-hormoon dat ACTH oftewel corticotropine uit 
de hypofyse vrijmaakt. In een muizenmodel werd de rol van IL-6 in de reactie van 
het immuunsysteem en de stimulatie van de HHB-as bestudeerd na infectie met 
micro-organismen, en na injectie met bacterieel endotoxine. IL-6 deficiënte muizen, 
welke niet in staat zijn om een volledige immuunrespons gedurende infectie te 
genereren, werden voor dit doel gebruikt. In een vissenmodel werd de bio-activiteit 
van CRH van rat (zoogdier) en tilapia (vis) met elkaar vergeleken, en de verdeling 
van CRH in de hersenen van tilapia werd bepaald na injectie met bacterieel 
endotoxine.
Hoofdstuk 1 begint met een korte inleiding over het begrip stress. Vervolgens 
wordt het concept van de bi-directionele communicatie tussen het neuro-endocriene 
en het immuunsysteem tijdens een ontsteking uitgelegd met informatie over 
interleukinen, IL-6 in het bijzonder, en CRH. Daarna is informatie gegeven over de 
verschillende infectiemodellen zoals die in dit proefschrift gebruikt zijn. Het 
onderzoek zoals beschreven in Hoofdstuk 2 t/m 5 concentreert zich op de rol van IL- 
6 in de reactie van de muis op infectie met micro-organismen. De studies werden 
uitgevoerd in IL-6 deficiente (IL-6-/-) muizen en hun wild-type (IL-6+/+) controles. 
Drie verschillende infectiemodellen werden gebruikt: Candida albicans (Hoofdstuk 
2), Yersinia enterocolitica (Hoofdstuk 3), en Klebsiella pneumoniae (Hoofdstuk 4). 
Na infectie met een van deze drie micro-organismen werd de overleving van de 
muizen en de uitgroei van de micro-organismen in verschillende organen bepaald. 
Onderzoek werd verricht naar de mogelijke rol van IL-6 in de reactie van het 
immuunsysteem en de HHB-as na infectie, en ook na injectie met gezuiverd 
endotoxine van Escherichia coli (Hoofdstuk 5). In de studies zoals beschreven in 
Hoofdstuk 6 en 7 werd de rol van CRH als centrale boodschapper van de HHK-as in 
beenvissen onderzocht in Oreochromis mossambicus (tilapia). De volgorde van 
bouwstenen (aminozuren) in tilapia CRH werd uitgezocht, en het vermogen van 
tilapia CRH om de afgifte van hormonen uit de hypofyse te stimuleren werd bepaald 
(Hoofdstuk 6). Tenslotte werden de reacties van de HHK-as op stress door het 
inperken van de leefomgeving en na injectie met endotoxine bestudeerd in tilapia 
(Hoofdstuk 7).
IL-6 is een multifunctioneel cytokine dat verschillende aspecten van de 
natuurlijke afweer van het immuunsysteem reguleert. Het is reeds eerder
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aangetoond dat endogeen IL-6 cruciaal is voor een efficiente verdediging tegen 
ernstige infecties met Gram-negatieve en Gram-positieve bacteria. Het doel van de 
studie beschreven in Hoofdstuk 2 was het onderzoeken van de rol van endogeen IL-
6 tijdens de verdediging tegen infectie met de gist C. albicans. Wij vonden dat 
gedurende experimentele candida infectie de IL-6-/- muizen een verminderde 
overlevingskans en een verhoogd aantal ziektekiemen in hun organen hadden in 
vergelijking met IL-6+/+ controle muizen, ondanks verhoogde concentraties van de 
cytokines TNF, IL-1 a en IL-1p in hun bloed. IL-6-/- muizen waren niet in staat om 
een efficiënte reactie van neutrofiele cellen tijdens de infectie te genereren. Wanneer 
muizen neutropeen (=neutrofiel arm) gemaakt werden door toediening van 
cyclophosphamide waren neutropene IL-6+/+ muizen even gevoelig voor C. albicans 
als neutropene IL-6-/- muizen, hetgeen betekent dat neutrofiele cellen het gunstige 
effect van endogeen IL-6 mediëren. Concluderend, IL-6-/- muizen zijn gevoeliger 
voor systemische candida infecties dan IL-6+/+ muizen, en IL-6 oefent zijn 
beschermend effect hoogstwaarschijnlijk uit via neutrofiele cellen.
In Hoofdstuk 3 onderzochten we of infectie van IL-6-/- muizen met het Gram- 
negatieve micro-organisme Y. enterocolitica ook wordt gekenmerkt door een gebrek 
aan vorming van neutrofiele cellen tijdens de infectie. Infectie van IL-6-/- muizen met 
Y. enterocolitica was gekenmerkt door een hogere mortaliteit dan infectie van IL- 
6+/+ muizen. Ondanks de hogere mortaliteit bevatten IL-6-/- muizen niet meer 
bacteriën in milt, lever, nieren, of mesenteriale lymfeklieren dan IL-6+/+ muizen, en 
in tegenstelling tot bevindingen bij andere infectiemodellen waren de met Yersinia 
geïnfecteerde IL-6-/- muizen wel in staat om een normale stijging van neutrofiele 
cellen in het bloed te ontwikkelen. We concluderen dat een gebrekkige reactie van 
neutrofiele cellen tijdens infecties niet een intrinsieke eigenschap van IL-6-/- muizen 
lijkt te zijn, maar afhankelijk is van de ziektekiem die de infectie veroorzaakt.
Gedurende bacteriële infecties worden zowel het immuunsysteem als de 
HHB-as geactiveerd. De rol van IL-6 bij de activatie van de HHB-as gedurende 
bacteriële infecties is niet duidelijk. IL-6 is waarschijnlijk een belangrijk cytokine in de 
wisselwerking tussen het immuunsysteem en de HHB-as, maar tot dusverre werd dit 
niet ondubbelzinnig aangetoond. De resultaten met het derde infectiemodel dat we 
gebruikt hebben om zowel immuun- als bijnierreacties te bestuderen in IL-6-/- en IL- 
6+/+ muizen werden gepresenteerd in Hoofdstuk 4. Het doel van deze studie was 
de rol van endogeen IL-6 te onderzoeken in de verdediging tegen een potentieel 
dodelijke infectie met K. pneumoniae, en in de daarmee gepaard gaande stimulatie 
van afgifte van glucocorticoiden door de bijnierschors. We toonden aan dat IL-6-/- 
muizen gevoeliger zijn dan IL-6+/+ muizen voor een systemische infectie met K. 
pneumoniae, met een hogere mortaliteit en een verhoogde uitgroei van micro- 
organismen in de lever, milt en nieren. Tevens vonden we een verzwakte 
aantrekking van neutrofiele cellen in het buikvlies. Daarnaast ging deze infectie 
gepaard met lagere concentraties corticosteron en hogere concentraties TNF in het 
bloed van IL-6-/- muizen dan in het bloed van IL-6+/+ muizen. We concluderen dat
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IL-6-/- muizen erg gevoelig zijn voor Gram-negatieve bacteriële infecties, hetgeen 
waarschijnlijk veroorzaakt wordt door met name een verzwakte aantrekking van 
neutrofiele cellen naar de plaats van infectie in de afwezigheid van IL-6. Voorts zou 
de verminderde reactie van de bijnier een verklaring kunnen zijn voor de sterkere 
ontstekingsreactie met hogere concentraties TNF in het bloed van IL-6-/- muizen dan 
in het bloed van IL-6+/+ muizen.
In Hoofdstuk 5 onderzochten we de rol van IL-6 met betrekking tot de afgifte 
van het bijnierschorshormoon corticosteron in muizen na injectie met een enkele 
dosis gezuiverd lipopolysaccharide (LPS), oftewel endotoxine, van E. coli. We 
bekeken de gevolgen van toediening van LPS in de buikholte (in een dosis varierend 
van 0,25 tot 2000 ^g per muis) op de concentraties van corticosteron, TNF en IL-1 in 
het bloed van IL-6-/- en IL-6+/+ muizen. De concentraties van corticosteron in het 
bloed stegen binnen een uur na LPS injectie bij beide muizenstammen. De stijging 
van de corticosteronspiegels in het bloed was significant minder sterk in IL-6-/- 
muizen, terwijl er geen verschillen tussen de twee muizenstammen werden 
gevonden in de stijging van de concentraties van TNF of IL-1 in het bloed. 
Vervolgens bestudeerden we de betrokkenheid van IL-1 of TNF in de reactie van IL- 
6-/- en IL-6+/+ muizen op LPS door continue infusie van muizen met een 
recombinant humane IL-1 receptorantagonist (IL-1ra), of door injectie met anti-TNFa 
antilichaam, respectievelijk. Voorbehandeling met IL-1 ra of anti-TNFa had geen 
invloed op de afgifte van corticosteron na injectie met LPS, noch in IL-6-/- noch in IL- 
6+/+ muizen. Concluderend duiden onze gegevens er op dat een gebrek aan 
endogeen IL-6 in muizen resulteert in een verminderde reactie van de bijnier op 
injectie met een enkele dosis gezuiverd endotoxine. We concluderen dat IL-1 en 
TNF niet noodzakelijk betrokken zijn in de activatie van de HHB-as van muizen na 
LPS toediening, maar dat IL-6 wel belangrijk is voor de reactie van de bijnier op LPS.
Naar aanleiding van de studies zoals beschreven in Hoofdstuk 2 t/m 5 van dit 
proefschrift kan geconcludeerd worden dat:
1. IL-6-/- muizen een hogere mortaliteit vertonen dan IL-6+/+ muizen in elk 
van de drie infectiemodellen die bestudeerd zijn (C. albicans, Y. 
enterocolitica en K. pneumoniae), daarmee aantonend dat endogeen IL-6 
van wezenljk belang is voor de overleving van de muizen gedurende 
infectie.
2. verhoogde concentraties van TNF en IL-1 in IL-6-/- muizen niet voldoende 
zijn om te compenseren voor IL-6 deficientie met betrekking tot 
bescherming tegen infectie met C. albicans of K. pneumoniae.
3. een verminderde reactie van neutrofiele cellen verantwoordelijk lijkt te zijn 
voor verhoogde uitgroei van ziektekiemen in de organen van IL-6-/- 
muizen gedurende de eerste dagen van infectie met C. albicans en K. 
pneumoniae.
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4. endogeen IL-6 noodzakelijk is voor een adequate reactie van de bijnier op 
infectie met K. pneumoniae en op injectie met bacterieel endotoxine van
E. coli. In deze twee modellen vonden we geen bewijs dat de cytokines IL- 
1 en TNF noodzakelijkerwijs betrokken zijn bij de activatie van de HHB-as.
In Hoofdstuk 6 en 7 van dit proefschrift onderzochten we de rol van CRH, een 
centrale regulator van de reactie op een stressor, in de beenvis tilapia. Hoewel het 
reeds duidelijk was dat CRH betrokken is bij de stress reactie in alle vertebraten, 
waren tot nu toe slechts een beperkt aantal studies over dit peptide gericht op 
neuroendocriene systemen anders dan bij zoogdieren.
In Hoofdstuk 6 bepaalden we de cDNA sequentie, oftewel de base volgorde 
(nucleotiden) coderend voor de voorloper van tilapia CRH en bestudeerden we de 
biologische potentie van het gesynthetiseerde CRH peptide in een bioassay 
gebruikmakend van de hypofyse van deze beenvis. Het gebruik van de Polymerase 
Ketting Reactie (PKR) met gedegenereerde en specifieke primers leverde 
fragmenten van het cDNA van tilapia CRH. De volledige lengte van het cDNA van 
CRH (988 nucleotiden) werd verkregen door een hypothalamus cDNA bank van 
tilapia te doorzoeken met de PKR producten van tilapia CRH. De afgeleide eiwit 
sequentie van het CRH voorloper molecuul (167 aminozuren) bevat een signaal 
peptide, het CRH-peptide zelf, en een motief dat in alle CRH-voorlopers van 
vertebraten geconserveerd is gebleven. Tilapia CRH (41 aminozuren) vertoont 
tussen 63% en 80% aminozuur sequentie-overeenkomst met CRH van andere 
vertebraten, terwijl de mate van overeenkomst met leden van de urotensine I / 
urocortine lijn (een verwant peptide) veel lager is. In een fylogenetische boom, 
gebaseerd op sequentie vergelijking van alle CRH-voorlopers die tegenwoordig 
bekend zijn, vormen de drie beenvis CRH-voorlopers een groep die zich 
onderscheidt van amfibische en zoogdier-voorlopers. Ondanks de verschillen tussen 
de primaire CRH structuren van tilapia en rat, waren maximaal effectieve 
concentraties van tilapia CRH en van rat CRH gelijkwaardig in het stimuleren van 
ACTH en a-MSH afgifte door tilapia hypofyses in vitro. De beenvis CRH sequenties 
tonen dat meer variatie aanwezig is tussen orthologe vertebraat CRH structuren (en 
beenvis CRHs in het bijzonder) dan voorheen bekend was. Of de structurele 
verschillen ook een weerspiegeling zijn van verschillende functies van dit peptide in 
de stress-reactie dient verder onderzocht te worden.
Het doel van de studie beschreven in Hoofdstuk 7 was het onderzoeken van 
de rol van CRH in de activatie van de HHK-as in tilapia. We bestudeerden de 
gevolgen van injectie van endotoxine-preparaten van E. coli en Vibrio cholerae op de 
HHK-as in tilapia tijdens normale condities en tijdens blootstelling aan een extra 
stressor, namelijk het inperken van de leefomgeving. De verdeling van 
immunoreactieve CRH-concentraties in de vissenhersenen, en de concentraties van 
chloride, glucose and cortisol in het bloed werden bepaald. De kwantitatieve analyse 
van de gehalten van CRH in de hersenen van tilapia na reactie op de injectie met
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endotoxine wees uit dat in het bijzonder E. coli LPS invloed heeft op de reactie van 
deze vis wanneer de leefomgeving ingeperkt wordt. Aangezien deze invloed 
betrekking heeft op osmoregulatoire, metabole en neuro-endocriene parameters, 
veronderstellen we dat wisselwerking tussen het geactiveerde immuunsysteem en 
het neuro-endocriene systeem plaatsvindt op meerdere organisatieniveau’s in tilapia. 
Het dient nog onderzocht te worden in welke mate CRH in de hersenen betrokken is 
bij deze regulatie mechanismen in deze diersoort, maar het is waarschijnlijk dat de 
rol van CRH in immuun-endocriene interacties een fylogenetisch oud mechanisme 
is.
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Nawoord
Gedurende de periode van studie en promotie is "thuis" voor mij altijd heel belangrijk 
gebleven. Papa1" en Mama, dank jullie wel voor een warme en veilige plek waar ik nog altijd 
terecht kan. Paul, fijn dat jij als broer en als beste vriend in staat bent om mijn "major life 
events" op een nuchtere manier te helpen relativeren.
Nog altijd herinner ik me de zonnige dag in het vroege voorjaar van 1993 dat ik voor 
een hele serie gesprekken op sollicitatiebezoek naar Nijmegen kwam. Ad en Fred van de 
"medische kant", Sjoerd en Paul van de "biologische kant", jullie allen ben ik zeer erkentelijk 
voor het vertrouwen dat jullie mij gegeven hebben om aan al de verschillende projecten en 
plannen te beginnen. Nog meer waardeer ik het dat jullie dat vertrouwen behouden hebben, 
ondanks de "major thesis events" onderweg, zodat ik de kans kreeg om dit proefschrift af te 
maken.
Het is schier onmogelijk om iedereen bij naam te noemen in dit nawoord, maar weet 
wel dat ik de samenwerking met en de hulp van vele personen het afgelopen decennium als 
zeer prettig ervaren heb. Geen enkel onderzoek is goed uit te voeren zonder de expertise en 
de ervaring van anderen. Mijn welgemeende dank gaat dan ook uit naar al die mensen van 
de laboratoria en de afdelingen waar ik als gast en als collega zeer welkom was.
Van het CDL heb ik prettige herinneringen aan het vele werk met ratjes en muizen. 
Mike bedank ik graag op deze plek, vooral omdat je me in de oude kelder het eerste jaar zo 
uitbundig hebt ingewerkt als collega lotgenoot van Endo. Met name bedank ik Yvette, Gerry, 
Hennie, Geert, Theo, Leo, Henk, en daarbij vele anderen voor al hun hulp bij de organisatie 
en uitvoering van mijn dierexperimenten en bij het (telkens weer) fokken van "mijn" ie-el-zes 
muizen. Yvette, we zijn allebei allergisch geworden voor muizen, maar ik krijg nog wel 
binnenpretjes als ik terugdenk aan onze verhalen op fluisterniveau.
Bij het oude LEV, tegenwoordig ACE, heb ik de werkdruk kunnen afwisselen met 
veel gezellige momenten. Voor hun hulp op het lab dank ik vooral Leon bij het overzicht, 
Dick en Willy bij de steroiden, Gerard, Mariëlle en Annemarie bij de ACTH en de cytokines, 
Joop en Doorlene bij de IL-6 controle bepalingen. Alec bedankt voor advies bij de statistiek, 
evenals Martin van de afdeling Medische Statistiek. Dank aan allen voor de collegialiteit.
Voor mijn onderzoek bij Organismale Dierfysiologie werd ik meteen al doorverwezen 
naar de groep Moleculaire Dierfysiologie van Gerard, die ik dan ook in het bijzonder dank 
voor zijn gastvrijheid. Tijdens het werk met RNA, DNA en isotopen heb ik dankbaar gebruik 
gemaakt van de kennis en ervaring van Eric, Karel en Peter. Ook was het erg leuk om mijn 
labruimte te delen met de andere "buitenbeentjes" Doug en Bianca. Bij Dierfysiologie dank ik 
Gert voor zijn terloopse adviezen, Ron en Tom voor de verzorging van de vissen en Declan 
voor de diepzinniger gesprekken over bijvoorbeeld "waterlelies uit het moeras". Vooral Peter 
ben ik zeer dankbaar voor het delen van experimenten en resultaten in de vorm van enkele 
posters en publicaties. Succes bij het verdere tilapia CRH onderzoek en je promotie.
Als gast bij de maandagmiddag werkbesprekingen van Interne Geneeskunde had ik 
veel profijt van de opbouwende kritiek van Jos en Bart Jan. Vooral Mihai dank ik zeer 
hartelijk voor het sturen en begeleiden van vele experimenten en twee hoofdstukken in dit 
proefschrift. Samenwerking met jullie afdeling heeft een heel bijzondere "immune" richting 
aan mijn "neuroendocrine" proefschrift gegeven.
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Bijzonder veel dank spreek ik uit voor de heel plezierige contacten die ik op 
verschillende wijzen en in verschillende perioden heb gehad met Pierre. Lab Interne was 
dankzij jouw inspanningen een fijne plek om aan een groot aantal van mijn experimenten 
meer inhoud te geven. Ineke, ontzettend bedankt voor alle cytokines die je voor mij 
tussendoor hebt gemeten.
Voor mijn experimenten in het CDL gebruikte ik vooral mannelijke muizen. Gelukkig 
was er sterke interesse voor de blote knietjes van de vrouwelijke muizen vanuit lab Rheuma 
van Wim. Fons en Onno, ik ben echt blij dat ik met jullie heb kunnen samenwerken, 
publiceren en nadenken over het fokken van "onze" ie-el-zes muizen.
De samenwerking en de levendige discussies met Rob en in een ander project met 
Jo van Microbiologie heb ik heel prettig gevonden. Ook Wim van CKCL bedank ik voor zijn 
expertise bij de microscopische differentiatie van witte muizenbloedcellen.
Jammer genoeg is niet van alle projecten een publicatie of hoofdstuk onstaan, maar 
ik kijk met genoegen terug op de besprekingen en de experimenten met Jan en Henk van 
Embryologie/ Anatomie en met Tony van Dierfysiologie om een eiwit/DNA dubbelkleuring in 
free floating coupes van ratten-, muizen- en vissenhersenen op te zetten.
Zonder de secretaresses van allerlei afdelingen was ik vast ergens vastgelopen. Met 
name Wil, Marieke, Lenny, Ingrid, Lot en Liesbeth dank ik voor hun hulp en de prettige 
gesprekken. Ik zal vast nog wel eens in de buurt zijn.
Aan het einde van mijn contract was er nog veel lab- en schrijfwerk te doen. Jack en 
Gert en Roland, in deze volgorde mijn "baas" sinds 2000, dank jullie wel voor de 
mogelijkheden die jullie me boden om me in de bioinformatica te bekwamen, terwijl ik nog 
moest publiceren en promoveren. Björn, "tack ska du ha" voor je Zweedse gastvrijheid in 
Malden. Voor alle anderen bij het CMBI, na mijn promotie blijf ik jullie collega.
Spanning en stress moeten afgewisseld worden met ontspanning om in een zeker 
evenwicht te blijven. Dankzij fijne vrienden waar ik leuke bezoekjes met wandel- of 
biertochten mee gehouden heb, en die nooit moe werden van mijn gepraat over stress en 
infecties en over knaagdieren en vissen en over eiwitten en DNA, ben ik telkens weer in 
balans kunnen komen. Voor mij is een actieve vorm van ontspannen het toeren met mijn 
motor, alleen, met twee, of met een groep. Vooral sinds 1997 heb ik erg veel plezier beleefd 
aan mijn hobby, zeker ook dankzij de evenementen in binnen- en buitenland vanuit de 
Yamaha Diversion Club Nederland. Allemaal, dank jullie wel, ik hoop jullie nog vele jaren na 
de afsluiting van deze periode te blijven ontmoeten.
Bijna aan het einde van dit nawoord wil ik even stilstaan bij de geweldige steun die ik 
heb mogen ontvangen van met name drie jongens, vroeger zelf promovendi, intussen 
vaders, en alledrie ook zeer belangrijk bij het afronden van dit proefschrift. Hans en Harry, 
mijn "paratroupers", en Paul, voor mij echt mijn "toegevoegd copromotor", ik dank jullie wel 
uit heel mijn hart.
Papa1, bedankt voor je wijze raad. Je woorden van ruim vijf jaar geleden staan nog 
altijd in mijn geheugen gegrift. Mijn proefschrift is nu klaar.
Frank
126
Curriculum Vitae
De schrijver van dit proefschrift werd op 13 januari 1967 geboren te Helden (L) en 
kreeg van zijn ouders de namen Frank Hendrik Johan van Enckevort. Na het behalen van 
het (ongedeeld) VWO diploma aan het St.-Antoniuscollege te Gouda in 1985 werd in 
datzelfde jaar begonnen met de studie Medische Biologie van de faculteit Geneeskunde aan 
de (toen nog Rijks-) Universiteit Utrecht. In het kader van het doctoraal examen deed hij als 
wetenschappelijke stages het bijvak "Biochemie" bij het Laboratorium voor Veterinaire 
Biochemie van de UU (Dr. M.J.H. Geelen en Dr. W.J. Vaartjes) en het hoofdvak "Moleculaire 
Parasitologie" bij het Laboratorium voor Parasitologie en Mycologie van het RIVM (Prof. Dr.
F. van Knapen en Dr. W.L. Homan), aangevuld met het afstudeervak "Moleculaire Biologie" 
bij de Vakgroep Moleculaire Celbiologie van de UU (Prof. Dr. H.O. Voorma). Op 28 oktober 
1991 werd het doctoraal examen Medische Biologie behaald en de dag erna werd het 
examen voor motorrijbevoegdheid succesvol afgelegd.
Na het afstuderen was hij verbonden aan het Laboratorium voor Parasitologie en 
Mycologie van het RIVM te Bilthoven voor onderzoek naar een manteleiwit van de 
parasitaire worm Trichinella spiralis met als doelstelling een vaccin tegen het larvale stadium 
te ontwikkelen. Daarop volgde in 1992 bij de vakgroep Experimentele Dierkunde van de 
Universiteit Utrecht (Prof. Dr. H.J.T. Goos en Dr. J. Bogerd) een tijdelijke aanstelling voor 
onderzoek naar genen die coderen voor steroidreceptoren behorend tot de hypothalamus- 
hypofyse-gonaden as.
Op 1 juni 1993 werd hij aangesteld als assistent in opleiding bij de afdeling 
Endocriene Ziekten (hoofd destijds Prof. Dr. P.W.C. Kloppenborg, gevolgd door Prof. Dr. 
A.G.H. Smals en tegenwoordig Prof. Dr. A.R.M.M. Hermus) en de afdeling Chemische 
Endocrinologie (hoofd destijds Prof. Dr. T.J. Benraad en tegenwoordig Dr. C.G.J. Sweep) 
van het Academisch Ziekenhuis Nijmegen (Universitair Medisch Centrum) St. Radboud. 
Aldaar werd gedurende anderhalf jaar onderzoek gedaan naar de rol van Nitric Oxide en 
NO-synthase remmers met betrekking tot de activatie van de hypothalamus-hypofyse-bijnier 
as tijdens ontstekings-reacties bij de rat. Vervolgens werd bij de afdeling Dierfysiologie 
(Prof. Dr. S.E. Wendelaar Bonga en Dr. P.H.M. Balm) van de Katholieke Universiteit 
Nijmegen gewerkt aan de sequentie analyse van het "corticotropin-releasing hormoon" 
(CRH) van de teleost Oreochromis mossambicus (tilapia), hetgeen een aanzet heeft 
gegeven voor vervolgonderzoek naar de activiteit van het gesynthetiseerd neuropeptide 
CRH in de vis. Van 1995 tot 1999 werd bij de afdeling Endocriene Ziekten en bij de afdeling 
Chemische Endocrinologie van het UMC Nijmegen onderzoek gedaan naar de rol van 
interleukine-6 bij de interactie tussen het immuunsysteem en de hypothalamus-hypofyse- 
bijnier as tijdens ontstekingsreacties bij de muis. De laatste twee projecten zijn beschreven 
in dit proefschrift.
Vanaf februari 2000 is hij werkzaam als data-manager en als onderzoeksassistent 
bioinformatica bij het Centrum voor Moleculaire en Biomoleculaire Informatica (CMBI, hoofd 
Prof. Dr. G. Vriend) van de Katholieke Universiteit Nijmegen. Per 1 november 2002 treedt hij 
in dienst bij het Nederlands Instituut voor Zuivel Onderzoek (NIZO food research) te Ede, 
werkzaam bij het CMBI in de groep van Prof. Dr. R.J. Siezen als post-doc in het vakgebied 
"Bacterial Genomics".
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